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ABSTRACT 
 
In normal metabolism, the binding of glucagon-like peptide 1 (GLP-1) to the glucagon-like 
peptide 1 receptor (GLP-1R) on pancreatic β cells prompts insulin production and secretion. T-
0632 is one of the few non-peptides that strongly binds to GLP-1R and is used to study the 
structure of the receptor. The current synthesis of T-0632 generates a racemic mixture, of which 
only one enantiomer is used in binding studies. Herein, we investigate the application of a steric 
chiral auxiliary, pi stacking chiral auxiliaries, and a pi stacking chiral catalyst to generate 
enantioselectivity in the synthesis of T-0632.   
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GC-MS: gas chromatography-mass spectrometry  
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1. INTRODUCTION 
 
1.1 Background  
 
As of 2011, it was suspected that 25.8 million people in the United States suffered from 
diabetes mellitus, a metabolic condition characterized by hyperglycemia.2 Of the roughly 18.8 
million diagnosed cases of diabetes in the United States, 90 – 95% of them were the result of 
type II diabetes, which is characterized by insulin resistance and/or abnormal insulin production 
and secretion.2,3 In addition to being the leading cause of non-traumatic lower limb amputations, 
blindness, and kidney failure, diabetes is associated with an increased risk of heart disease and 
stroke and is the seventh leading cause of death in the United States.2 Although lifestyle changes 
such as a well-balanced diet and daily exercise can help prevent type II diabetes and its 
complications, these changes are expensive to implement and often cannot be implemented by 
individuals in lower socioeconomic classes.3 Because these preventative measures are not 
practical for individuals in lower socioeconomic groups, the risk of diagnosed diabetes is 66% 
higher for Hispanics and 77% higher for non-Hispanic blacks than for non-Hispanic whites.2 To 
combat the systematic injustice inherent in the use of these lifestyle changes as preventive 
measures, an effective, low-cost treatment option that is accessible to all socioeconomic and 
ethnic groups needs to be developed. This demand is pressing because an estimated 300 million 
people worldwide will suffer from diabetes by 2025.3 
Many non-lifestyle based treatment options for type II diabetes revolve around the 
incretin hormone glucagon-like peptide 1 (GLP-1). Upon the ingestion of food and subsequent 
rise in blood sugar levels, the intestine secretes GLP-1 into the bloodstream.4 GLP-1 travels 
through the body and binds to glucagon-like peptide 1 receptor (GLP-1R), a class B G-protein 
coupled receptor.5 Upon the binding of GLP-1 to GLP-1R on pancreatic β cells, adenylyl cyclase 
	   7 
is activated, leading to the production of cyclic adenosine monophosphate (cAMP).6 As shown in 
Figure 1, the rise in cAMP results in the activation of protein kinase A (PKA) and exchange 
proteins directly associated with 
cAMP (known as Epac).6 Activation 
of PKA causes the phosphorylation 
and subsequent closure of adenosine 
triphosphate (ATP) sensitive K+ 
channels (KATP).6 As blood glucose 
levels increase, the glucose 
transporters GLUT1 and GLUT2 
transport glucose into pancreatic β 
cells, where it is metabolized to 
generate ATP.6,7 The increase in the 
concentration of ATP following 
glucose metabolism further aids the 
closure of KATP.6 The closure of 
KATP prompts depolarization of the 
cell membrane, which causes 
voltage-dependent Ca2+ channels to 
open and Ca2+ to rush into the cell.6 The influx of Ca2+ triggered by PKA activation and glucose 
metabolism is accompanied by Epac triggered release of Ca2+ from the endoplasmic reticulum.6 
The resultant increase in the intracellular concentration of Ca2+ prompts the exocytosis of 
insulin-containing secretory vesicles.8 In this way, GLP-1 stimulates glucose-dependent insulin 
Figure 1. Simplified drawing outlining the role of glucagon-
like peptide 1 (GLP-1) and glucagon-like peptide 1 receptor 
(GLP-1R) in glucose-dependent insulin secretion from 
pancreatic β cells. Upon the binding of GLP-1 to GLP-1R, 
cAMP is produced and PKA is activated. Activation of PKA 
prompts the closure of ATP sensitive K+ channels (K-ATP), 
which is further aided by the intracellular metabolism of 
glucose. The closure of K-ATP channels leads to 
depolarization of the cell membrane, which triggers the 
opening of voltage gated Ca2+ channels (Ca-VS). The resulting 
influx of Ca2+ prompts insulin exocytosis. Repolarization of 
the cell membrane occurs through opening of Ca2+ sensitive K+ 
channels (K-Ca). Reprinted from LeRoith et al.1 
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secretion from pancreatic β cells. The insulin secreted from pancreatic β cells stimulates other 
cells throughout the body to uptake glucose, thereby lowering blood glucose levels.9 
In patients with type II diabetes, glucose-dependent insulin secretion from pancreatic β cells 
is impaired.10 Due to the vital role of GLP-1 in glucose-dependent insulin secretion, GLP-1 
centered treatments for type II diabetes have received a considerable amount of attention. GLP-1 
itself is not an effective treatment option, however, because its half-life in the bloodstream is less 
than 2 minutes.11 For GLP-1 administration to be an effective treatment option, it must be 
intravenously infused continuously into the bloodstream, which is highly impractical from a 
patient compliance standpoint.12 As a result of this limitation, GLP-1 centered treatments for 
type II diabetes have taken a two-pronged indirect approach, as shown in Figure 2. Whereas the 
first approach relies upon reproducing the effects of GLP-1 at pancreatic β cells, the second 
approach focuses on enhancing the effective concentration of GLP-1 in the bloodstream.  
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Figure 2.	  GLP-1 centered treatments for type II diabetes. The first approach uses peptide and 
small molecule agonists of GLP-1R to mimic the action of GLP-1. The second approach 
enhances the effects of GLP-1 by preventing its degradation or by stimulating its secretion. 
Adapted from Cho et al.13 	  
To increase the effective concentration of GLP-1 in the bloodstream, researchers have 
focused on preventing GLP-1 degradation. To achieve this goal, researchers have designed 
molecules that inhibit dipeptidyl peptidase IV (DPP-IV), a protease that cleaves GLP-1 after 
alanine 2, thereby making it inactive.14 By inhibiting DPP-IV, GLP-1 stimulates pancreatic β 
cells for a longer period of time and increases the amount of insulin secreted.15 Although this 
approach has resulted in the development of several highly successful drugs, this type of 
treatment is unsuccessful when GLP-1 is not secreted from the intestines, which is common in 
patients suffering from type II diabetes.16 The ineffectiveness of DPP-IV inhibitors in these 
situations has prompted the development of two new classes of molecules. The first class of 
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molecules, known as GLP-1 secretagogues, prompt GLP-1 secretion whereas the second class of 
molecules, known as GLP-1R agonistsA, bind to GLP-1R and subsequently prompt glucose-
dependent insulin secretion. The majority of research from the past decade has centered upon the 
development of GLP-1R agonists.  
 Many of the GLP-1R agonists that have been developed to treat type II diabetes are 
peptides. The two most common peptide agonists being used in treatment are exenatide and 
liraglutide.  Exenatide is a synthetic form of exendin-4, a peptide isolated from the saliva of the 
Gila monster Heloderma suspectum.17 Although exenatide exhibits 53% amino acid homology 
with human GLP-1, the replacement of alanine 2 in GLP-1 with a glycine residue in exenatide 
makes the peptide resistant to DDP-IV cleavage.17 As a result, the half-life of exenatide is 6 
hours, which is 180 times as long as the half-life of GLP-1.17 The prolonged half-life of 
exenatide leads to the extended stimulation of GLP-1R, a consequence of which is increased 
glucose-dependent insulin secretion.18  
A similar peptide agonist of GLP-1R is liraglutide. Liraglutide is a synthetic analogue of 
GLP-1 that contains a palmitoyl fatty acid modified lysine residue rather than an arginine residue 
at position 34.19 This modification makes the analogue resistant to degradation by DPP-IV, 
resulting in a half-life of roughly 12 hours, which is 360 times as long as the half life of GLP-1.19 
As with exenatide, a consequence of the prolonged half-life of liraglutide is increased stimulation 
of GLP-1R and increased glucose-dependent insulin secretion.  
Despite the effectiveness of both exenatide and liraglutide in prompting and prolonging 
insulin secretion, these treatment options are far from ideal. Treatment with exenatide has 
resulted in the production of anti-exenatide antibodies in 50% of patients receiving the twice 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
AAgonist: A chemical that binds to the receptor and triggers a response that typically mimics the 
response induced by the endogenous chemical.  
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daily treatment.18 The formation of such antibodies may result in therapeutic inefficacy over 
time. Nausea and vomiting are frequently reported side effects of exenatide or liraglutide, and 
both drugs have been cited in the development of acute pancreatitisB.18 Additionally, because 
both exenatide and liraglutide are peptides, oral administration leads to denaturation in the 
stomach before reaching GLP-1R. This complication requires the peptides to be administered 
through daily subcutaneous injections, which does not lend itself to long-term patient 
compliance.18 
The major drawbacks associated with the administration of these peptide agonists have 
prompted researchers to develop non-peptide GLP-1R agonists. Although this approach seems 
logical, it has been very inefficient. After screening a quarter of a million small molecules with a 
functional assay and making structural modifications to the promising hits, researchers identified 
2-(2’-methyl)thiadiazolylsulfanyl-3-trifluoromethyl-6,7-dichloroquinoxaline, shown in Figure 3,	  
as an agonist of human GLP-1R and not as an agonist of the 
closely related glucagon-like peptide 2, glucagon, and 
gastrointestinal peptide receptors.20 The compound was also 
found to affect the binding of GLP-1 to GLP-1R in a 
concentration dependent manner, suggesting that it was also an 
allosteric modulator of GLP-1R.20 Despite its promise as a non-
peptide GLP-1R agonist, the compound’s duality as both an 
agonist and allosteric effector was worrisome because it 
prevented doctors from predicting with certainty how the compound would act once inside the 
human body.20  
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The lack of success in finding a non-peptide 
agonist of GLP-1R through the screening and 
subsequent optimization of small molecules has 
been accompanied by the accidental discovery of 
GLP-1R antagonistsC. In 1998, a Japanese 
pharmaceutical company developed T-0632, a 
small molecule designed to treat pancreatitis.21 
Recall that binding of GLP-1 to GLP-1R on 
pancreatic β cells stimulates the production of 
cAMP, which subsequently triggers various events 
that lead to the glucose-dependent secretion of 
insulin.6 As shown in Figure 4, Beinborn and coworkers found that T-0632 hampered the 
production of cAMP, suggesting that the secretion of insulin from these cells was impaired.  A 
closer look at Figure 4 reveals that T-0632 reduced cAMP production more when bound to 
human GLP-1R than rat GLP-1R. The researchers attributed this to the 9% amino acid sequence 
inhomology between the human and rat receptors.22 
In order to determine which amino acid inhomologies contributed most to the difference in 
T-0632 potency at the human GLP-1R and rat GLP-1R, the researchers created human-rat GLP-
1R chimerasD. A schematic diagram detailing the construction of the chimeras is shown in Figure 
5. Although all of the chimeras contained the amino terminus of human GLP-1R and the 
carboxyl terminus of rat GLP-1R, the ratio of the human receptor portion to the rat receptor 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
CAntagonist: A chemical that binds to the receptor without triggering the response induced by the 
endogenous chemical.  
DChimera: A substance or part created from the genes of at least two different species.  
potentially contribute to T-0632 affinity, we constructed and
characterized a series of chimeric GLP-1 receptors. The chime-
ras included amino-terminal portions from the human receptor
protein complemented by increasing carboxyl-terminal substi-
tutions from the rat homolog (Fig. 5). Competition binding
experiments utilizing these receptors revealed that even a lim-
ited amino-terminal domain of the human GLP-1 receptor (note
the PvuI chimera in Fig. 5) was sufficient to maintain T-0632
affinity close to the value observed at the wild type human
protein. T-0632 affinity was conserved despite the fact that
most of the PvuI chimera consisted of rat GLP-1 receptor amino
acids, and only eight residues within the amino terminus re-
mained as candidate T-0632 affinity determinants.
To explore further the role of these residues, we sequentially
replaced each of the remaining eight candidates in the human
GLP-1 receptor with homologous amino acids in the rat GLP-1
receptor (Fig. 6). Radioligand competition experiments at these
point mutants revealed that replacement of tryptophan at po-
sition 33 in the human receptor by its homolog in the rat
receptor, serine, significantly decreased T-0632 affinity close to
the value observed at the rat wild type protein. In contrast,
substitution of the remaining candidate amino acids, alone or
in combination, had no effect on T-0632 binding.
The marked loss of T-0632 affinity at the W33S mutant
suggested that this residue plays an important role in com-
pound binding. To further explore this hypothesis, a converse
experiment was performed in which the serine residue in po-
sition 33 of the rat GLP-1 receptor was substituted with its
human homolog, tryptophan. As illustrated in Fig. 7A, radioli-
gand competition at the S33W rat receptor mutant by T-0632
approached the level observed at the wild type human GLP-1
receptor. Further analysis of T-0632 binding over a broad con-
centration range showed that exchange of the residues occupy-
ing position 33 in the human (W) versus rat receptors (S) was
sufficient to reverse the affinities observed at respective wild
type proteins (Fig. 7B). The calculated affinity of T-0632 at the
rat S33W mutant exceeds the corresponding value at the hu-
man W33S mutant by more than 100-fold. Thus, both loss-of-
function and gain-of-function experiments support the conclu-
FIG. 2. T-0632 acts as a more potent antagonist at the human
than at the rat GLP-1 receptor. GLP-1 (2 ! 10"11 M)-induced pro-
duction of cAMP was assessed in COS-7 cells expressing either the
human (f) or the rat GLP-1 receptor (!) in the presence of increasing
concentrations of T-0632. All values were normalized to GLP-1-induced
cAMP production in the absence of T-0632 (#100%; 4.3 $ 1.0 and 3.6 $
0.8 pmol/well for the human and rat receptors, respectively). The IC50
values of T-0632 were 21 !M (CI, 9–49) at the human and 353 !M (CI,
199–625) at the rat GLP-1 receptors, respectively. Data represent
means and either S.E. or CI of six independent experiments.
FIG. 3. T-0632 is a non-competitive inhibitor of GLP-1-induced
cAMP production. GLP-1-induced production of cAMP was assessed
in COS-7 cells expressing the human GLP-1 receptor, either in the
absence (f) or presence of 2.3 ! 10"4 M T-0632 (!). Presence of T-0632
shifted the EC50 of GLP-1 from 134 (CI, 88–202) to 506 pM (CI, 301–
850), with a concomitant decrease in maximal stimulation. Values
represent means and either S.E. or CI of four paired experiments, each
performed in the absence or presence of T-0632. Asterisks indicate a
significant difference between GLP-1 (10"6 M)-induced cAMP produc-
tion in the absence versus presence of T-0632 (p % 0.01; paired t test).
FIG. 4. The human and rat GLP-1 receptors differ at 42 amino
acid positions. The cartoon symbolizes the seven-transmembrane to-
pology of GLP-1 receptors. Amino acids that are identical in the human
and rat receptor species homologs are shown as open circles (91%
overall identity), whereas residues that differ are shown as closed
circles. The location of the plasma membrane bilayer is indicated by two
parallel lines. The positions corresponding to cDNA restriction sites for
PvuI, BstXI, EcoRI, XhoI, and AflII are marked by arrows. NH2 indi-
cates the amino terminus, and COOH indicates the carboxyl terminus.
FIG. 5. High affinity binding of T-0632 is determined by the
amino terminus of the human GLP-1 receptor. Cartoons symbolize
the human and rat wild type GLP-1 receptors (shown as black and gray
line graphs, respectively), as well as chimeric constructs of the human
receptor with increasing carboxyl-terminal contributions from the rat
species homolog. The AflII, XhoI, EcoRI, BstXI, and PvuI chimeras were
generated as detailed under “Methods.” Binding of 125I exendin (9–39)
was assessed using COS-7 cells expressing respective receptor con-
structs. Non-displaceable binding in the presence of 20 !M T-0632 was
normalized to control binding in the absence of compound (100%). Data
represent means $ S.E. of n independent experiments as indicated in
the figure. N indicates the amino terminus; C indicates the carboxyl
terminus, and asterisks indicate significance versus non-displaceable
binding (& T-0632) at the human GLP-1 receptor (p% 0.01 by ANOVA).
Glucagon-like Peptide 1 Receptor Small Molecule Ligand 37789
 at W
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Downloaded from 
Figure 4. T-0632 is more potent at reducing 
GLP-1 induced cAMP production when bound 
to human GLP-1R than to rat GLP-1R. T-0632 
had an IC50 value of 21 µM at the human 
receptor and 353 µM at the rat receptor when 
the concentration of GLP-1 was 20 pM. The 
IC50 value is the concentration ne ded to inhibit 
a biological process by 50%. Reprinted from 
Beinborn and coworkers.  
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portion differed between the 
chimeras. The arrows in Figure 5 
show the residue in the chimera 
where the human receptor portion 
ended and the rat receptor portion 
began.  
The researchers used 25I 
exendin-4 to examine the strength 
with which T-0632 bound to 
human GLP-1R, rat GLP-1R, and 
the various human-rat GLP-1R 
chimeras. The results of these 
competition-binding studies are 
shown in Figure 6. As can be seen in the first two rows of the figure, T-0632 bound significantly 
more strongly to human GLP-1R than to rat GLP-1R. Surprisingly, T-0632 bound as tightly to 
human GLP-1R as to all of the human-rat GLP-1R chimeras. It is interesting to note that T-0632 
bound as tightly to human GLP-1R as to the PvuI chimera, which only contained the first 49 
amino acid residues of the human receptor.  The similarity in the strength with which T-0632 
bound to human GLP-1R and to the PvuI chimera suggested that the amino acid sequence 
common to both receptors determined the strength with which T-0632 bound to any type of 
GLP-1R. In other words, differences within the first 49 amino acid residues were believed to be 
responsible for the difference in the strength with which T-0632 bound to human GLP-1R and to 
rat GLP-1R.  
potentially contribute to T-0632 affinity, we constructed and
characterized a series of chim ric GLP-1 r ceptors. The chime-
ras included amino-terminal portions from the human receptor
protein complemented by increasing carboxyl-terminal substi-
tutions from the rat homolog (Fig. 5). Competition binding
experiments utilizing these receptors revealed that even a lim-
ited amino-terminal domain of the human GLP-1 receptor (note
the PvuI chimera in Fig. 5) was sufficient to maintain T-0632
affinity close to the value observed at the wild type human
protein. T-0632 affinity was conserved despite the fact that
most of the PvuI chimera consisted of rat GLP-1 receptor amino
acids, and only eight residues within the amino terminus re-
mained as candidate T-0632 affinity determinants.
To explore further the role of these residues, we sequentially
replaced each of the remaining eight candidates in the human
GLP-1 receptor with homologous amino acids in the rat GLP-1
receptor (Fig. 6). Radioligand competition experiments at these
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sition 33 in the human receptor by its homolog in the rat
receptor, serine, significantly decreased T-0632 affinity close to
the value observed at the rat wild type protein. In contrast,
substitution of the remaining candidate amino acids, alone or
in combination, had no effect on T-0632 binding.
The marked loss of T-0632 affinity at the W33S mutant
suggested that this residue plays an important role in com-
pound binding. To further explore this hypothesis, a converse
experiment was performed in which the serine residue in po-
sition 33 of the rat GLP-1 receptor was substituted with its
human homolog, tryptophan. As illustrated in Fig. 7A, radioli-
gand competition at the S33W rat receptor mutant by T-0632
approached the level observed at the wild type human GLP-1
receptor. Further analysis of T-0632 binding over a broad con-
centration range showed that exchange of the residues occupy-
ing position 33 in the human (W) versus rat receptors (S) was
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than at the rat GLP-1 receptor. GLP-1 (2 ! 10"11 M)-induced pro-
duction of cAMP was assessed in COS-7 cells expressing either the
human (f) or the rat GLP-1 receptor (!) in the presence of increasing
concentrations of T-0632. All values were normalized to GLP-1-induced
cAMP production in the absence of T-0632 (#100%; 4.3 $ 1.0 and 3.6 $
0.8 pmol/well for the human and rat receptors, respectively). The IC50
values of T-0632 were 21 !M (CI, 9–49) at the human and 353 !M (CI,
199–625) at the rat GLP-1 receptors, respectively. Data represent
means and either S.E. or CI of six independent experiments.
FIG. 3. T-0632 is a non-competitive inhibitor of GLP-1-induced
cAMP production. GLP-1-induced production of cAMP was assessed
in COS-7 cells expressing the human GLP-1 receptor, either in the
absence (f) or presence of 2.3 ! 10"4 M T-0632 (!). Presence of T-0632
shifted the EC50 of GLP-1 from 134 (CI, 88–202) to 506 pM (CI, 301–
850), with a concomitant decrease in maximal stimulation. Values
represent means and either S.E. or CI of four paired experiments, each
performed in the absence or presence of T-0632. Asterisks indicate a
significant difference between GLP-1 (10"6 M)-induced cAMP produc-
tion in the absence versus presence of T-0632 (p % 0.01; paired t test).
FIG. 4. The human and rat GLP-1 receptors differ at 42 amino
acid positions. The cartoon symbolizes the seven-transmembrane to-
pology of GLP-1 receptors. Amino acids that are identical in the human
and rat receptor species homologs are shown as open circles (91%
overall identity), whereas residues that differ are shown as closed
circles. The location of the plasma membrane bilayer is indicated by two
parallel lines. The positions corresponding to cDNA restriction sites for
PvuI, BstXI, EcoRI, XhoI, and AflII are marked by arrows. NH2 indi-
cates the amino terminus, and COOH indicates the carboxyl terminus.
FIG. 5. High affinity binding of T-0632 is determined by the
amino terminus of the human GLP-1 receptor. Cartoons symbolize
the human and rat wild type GLP-1 receptors (shown as black and gray
line graphs, respectively), as well as chimeric constructs of the human
receptor with increasing carboxyl-terminal contributions from the rat
species homolog. The AflII, XhoI, EcoRI, BstXI, and PvuI chimeras were
generated as detailed under “Methods.” Binding of 125I exendin (9–39)
was assessed using COS-7 cells expressing respective receptor con-
structs. Non-displaceable binding in the presence of 20 !M T-0632 was
normalized to control binding in the absence of compound (100%). Data
represent means $ S.E. of n independent experiments as indicated in
the figure. N indicates the amino terminus; C indicates the carboxyl
terminus, and asterisks indicate significance versus non-displaceable
binding (& T-0632) at the human GLP-1 receptor (p% 0.01 by ANOVA).














Figure 5.	  Schematic diagram of	  human GLP-1R embedded 
with the cell membrane. Amino acid residues that are 
identical in human GLP-1R and rat GLP-1R are shown as 
op n circles, and amino acid residues that are different in 
human GLP-1R and rat GLP-1R are shown as closed 
circles. The residues where the human receptor portion 
ended and the rat receptor portion began in the chimeras 
PvuI, BstXI, EcoRI, XhoI, and AflII are indicated with 
arrows. Adapted from Beinborn and coworkers. 	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 The black circles in Figure 5 
indicate the positions where the amino acid 
residues within human GLP-1R differ from 
the amino acid residues within rat GLP-1R. 
As can be seen in the figure, there are 8 
amino acid residues within the first 49 
residues where the amino acid sequences of 
human GLP-1R and rat GLP-1R do not 
match.22 To determine which of these 
residues was most important for T-0632 
binding, the researchers sequentially 
replaced the amino acids in the amino 
terminus of the human receptor with those 
amino acids at the corresponding position in 
the rat receptor. The replacement of tryptophan 33 with a serine residue significantly reduced the 
strength with which T-0632 bound to the receptor, suggesting the importance of the tryptophan 
33 residue in T-0632 binding.22 To further explore the importance of tryptophan 33 in T-0632 
binding, the researchers replaced it with the following residues: phenylalanine, tyrosine, alanine, 
histidine, and glutamine. Although all of these substitutions resulted in decreased T-0632 binding 
affinity, the phenylalanine and tyrosine substitutions preserved T-0632 binding affinity the most, 
suggesting the importance of aromatic interactions in non-peptide binding to GLP-1R.22 More 
biological binding studies using T-0632 are necessary in order to fully understand non-peptide 
binding at GLP-1R. This information can be used to intelligently design non-peptide drugs that 
potentially contribute to T-0632 affinity, we constructed and
characterized a series of chimeric GLP-1 receptors. The chime-
ras included amino-terminal portions from the human receptor
protein complemented by increasing carboxyl-terminal substi-
tutions from the rat homolog (Fig. 5). Competition binding
e eriments utilizing these receptors revealed that even a lim-
ited amino-terminal domain of the human GLP-1 receptor (note
the PvuI chimera in Fig. 5) was sufficient to maintain T-0632
affinity close to the value observed at the wild type human
protein. T-0632 affinity was conserved despite the fact that
most of the PvuI chimera consisted of rat GLP-1 receptor amino
acids, and only eight residues within the amino terminus re-
mained as candidate T-0632 affinity determinants.
To explore further the role of these residues, we sequentially
replaced each of the remaining eight candidates in the human
GLP-1 receptor with homologous amino acids in the rat GLP-1
receptor (Fig. 6). Radioligand competition experiments at these
point mutants revealed that replacement of tryptophan at po-
sition 33 in the human receptor by its homolog in the rat
receptor, serine, significantly decreased T-0632 affinity close to
the value observed at the rat wild type protein. In contrast,
substitution of the remaining candidate amino acids, alone or
in combination, had no effect on T-0632 binding.
The marked loss of T-0632 affinity at the W33S mutant
suggested that this residue plays an important role in com-
pound binding. To further explore this hypothesis, a converse
experiment was performed in which the serine residue in po-
sition 33 of the rat GLP-1 receptor was substituted with its
human homolog, tryptophan. As illustrated in Fig. 7A, radioli-
gand competition at the S33W rat receptor mutant by T-0632
approached the level observed at the wild type human GLP-1
receptor. Further analysis of T-0632 binding over a broad con-
centration range showed that exchange of the residues occupy-
ing position 33 in the human (W) versus rat receptors (S) was
sufficient to reverse the affinities observed at respective wild
type proteins (Fig. 7B). The calculated affinity of T-0632 at the
rat S33W mutant exceeds the corresponding value at the hu-
man W33S mutant by more than 100-fold. Thus, both loss-of-
function and gain-of-function experiments support the conclu-
FIG. 2. T-0632 acts as a more potent antagonist at the human
than at the rat GLP-1 receptor. GLP-1 (2 ! 10"11 M)-induced pro-
duction of cAMP was assessed in COS-7 cells expressing either the
human (f) or the rat GLP-1 receptor (!) in the presence of increasing
concentrations of T-0632. All values were normalized to GLP-1-induced
cAMP production in the absence of T-0632 (#100%; 4.3 $ 1.0 an 3.6 $
0.8 pmol/well for the human and rat receptors, respectively). The IC50
values of T-0632 were 21 !M (CI, 9–49) at the human and 353 !M (CI,
199–625) at the rat GLP-1 receptors, respectively. Data represent
means and either S.E. or CI of six independent experiments.
FIG. 3. T-0632 is a non-competitive inhibitor of GLP-1-induced
cAMP production. GLP-1-induced production of cAMP was assessed
in COS-7 cells expressing the human GLP-1 receptor, either in the
absence (f) or presence of 2.3 ! 10"4 M T-0632 (!). Presence of T-0632
shifted the EC50 of GLP-1 from 134 (CI, 88–202) to 506 pM (CI, 301–
850), with a concomitant decrease in maximal stimulation. Values
represent means and either S.E. or CI of four paired experim nts, eac
performed in the absence or presence of T-0632. Asterisks indicate a
significant difference between GLP-1 (10"6 M)-induced cAMP produc-
tion in the absence versus presence of T-0632 (p % 0.01; paired t test).
FIG. 4. The human and rat GLP-1 receptors differ at 42 amino
acid positions. The cartoon symbolizes the seven-transmembrane to-
pology of GLP-1 receptors. Amino acids that are identical in the human
and rat receptor species homologs are shown as open circles (91%
overall identity), whereas residues that differ are shown as closed
circles. The location of the plasma membrane bilayer is indicated by two
parallel lines. The positions corresponding to cDNA restriction sites for
PvuI, BstXI, EcoRI, XhoI, and AflII are marked by arrows. NH2 indi-
cates the amino terminus, and COOH indicates the carboxyl terminus.
FIG. 5. High affinity binding of T-0632 is determined by the
amino terminus of the human GLP-1 receptor. Cartoons symbolize
the human and rat wild type GLP-1 receptors (shown as black and gray
line graphs, respectively), as well as chimeric constructs of the human
receptor with increasing carboxyl-terminal contributions from the rat
species homolog. The AflII, XhoI, EcoRI, BstXI, and PvuI chimeras were
generated as detailed under “Methods.” Binding of 125I exendin (9–39)
was assessed using COS-7 cells expressing respective receptor con-
structs. Non-displaceable binding in the presence of 20 !M T-0632 was
normalized to control binding in the absence of compound (100%). Data
represent means $ S.E. of n independent experiments as indicated in
the figure. N indicates the amino terminus; C indicates the carboxyl
terminus, and asterisks indicate significance versus non-displaceable
binding (& T-0632) at the human GLP-1 receptor (p% 0.01 by ANOVA).
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Figure 6.	  The strength with which	  T-0632 bound to 
human GLP-1R, rat GLP-1R, and human-rat GLP-1R 
chimeras. The bolded lines represent the portions of the 
receptors that contained amino ac ds fr m the human 
receptor, and the gray lines represent the portions of the 
receptors that contained amino acids from the rat 
receptor. The concentration of T-0632 was 20 µM. 
Reprinted from Beinborn and coworkers.  
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activate the signal transduction cascade responsible for glucose-dependent insulin secretion upon 
binding to GLP-1R.  
The pharmaceutical company that first manufactured T-0632 no longer synthesizes it 
because it was not a viable treatment option for pancreatitis. Although the synthesis of pure T-
0632 was published and patented, this synthesis was not reproducible in the Haines lab. As 
shown in Figure 7, previous student researchers developed a synthetic route for the production of 
T-0632, which will herein be referred to as T-06.23 
	  
Figure 7.	  The synthetic route for racemic T-06 developed by the Haines lab. The chiral center is 
highlighted with a red asterisk. The major product of each synthetic step is numbered in bold.  	  
This synthetic route is not ideal because racemic T-06 is generated. Only the S 
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roughly 50% of the T-06 generated is not used in biological testing. This work has focused on 
revising the current synthesis so that enantiomeric excess is generated, thereby making the 
synthetic route more efficient.   
1.2 Stereoselective Synthesis of T-0632 
As shown in Figure 7, racemization is first produced in the fourth step of the synthesis 
when the oxime 3 is reduced to the amine hydrochloride 4 via catalytic hydrogenation. 
Controlling the 
stereochemistry at this 
step of the reaction is 
futile because the 
resulting 
stereochemistry is lost 
in the sixth step of the 
synthesis. As shown in Figure 8, base-catalyzed deprotonation of the chiral center generates a T-
07 carbanion 5.i that is resonance stabilized by a carbonyl that is alpha to it. As a result of 
resonance stabilization, the T-07 carbanion 5.i is expected to be sp2 hybridized and trigonal 
planar in geometry. The hypothesized planar geometry of the T-07 carbanion 5.i suggests that 
nucleophilic attack is as likely to occur at one side of the Michael acceptor as it is at the other 
side of the Michael acceptor. If the T-07 carbanion 5.i can be forced into preferentially attacking 
the Michael acceptor from one side rather than the other side, the reaction will be stereoselective. 



















Figure 8. The intermediate in the sixth step of the synthesis of racemic 
T-06 7 is the T-07 carbanion 5.i. 
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1.2.1 Steric Approach     
The first approach towards generating stereoselectivity relied upon a steric chiral 
auxiliaryE.24 As shown in Figure 9, isobornyl acrylate was substituted for methyl acrylate in the 
sixth step of the synthesis. We expected the bulkiness of the isobornyl group to force 
stereospecific nucleophilic attack by the T-07 carbanion 5.i, thereby generating a major and 
minor T-06 isobornyl ester 6.A diastereomer. After separating the diastereomers via column 
chromatography, the diastereomers could be base hydrolyzed to form a major and minor T-06 7 
enantiomer.  
 
Figure 9.	  Michael addition of T-07 5 to isobornyl acrylate A generates T-06 isobornyl ester 6.A 
diastereomers. 
1.2.2 Pi Stacking Approach  
In contrast to the first approach, the second approach relied upon the formation of pi 
stacking interactions. Non-covalent pi stacking interactions are commonplace in molecular 
biology and chemistry. They play a major role in the vertical base pair stacking within DNA, the 
packing of aromatic compounds in crystals, the tertiary structure of proteins, porphyrin 
aggregation, and self-assembly in supramolecular aggregates.25,26 The earliest model of pi 
stacking interactions was developed by Hunter and Saunders in the early 1990s. Their 
electrostatic model suggests that pi stacking interactions occur when the attractive interactions 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
E Chiral auxiliary:  a chemical unit that is temporarily incorporated into a compound in order to 
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between π electrons and the σ framework outweigh the repulsive interactions between pi 
electrons.25 Based upon agreement between ab initio calculations and experimental observations 
of porphyrin molecules, Hunter and Saunders concluded that three major pi-stacking geometries 
exist: face-face, edge-face, and offset face, all of which are shown in Figure 10.25  
 
Figure 10.	  Pi stacking geometries of the benzene dimer. The electrostatic potential energy 
surface is mapped around each benzene molecule. Red corresponds to regions of negative 
electrostatic potential energy, and blue corresponds to regions of positive electrostatic potential 
energy. The face-face geometry is the least energetically favorable. The edge-face and offset face 
geometries are the most energetically favorable. Images were generated with Gaussview using 
Hartree-Frock method and 6-311g + (d, p) basis set. 	  
For non-polarized pi systems such as benzene, the π electrons create a quadruple 
moment, causing partial negative charge to accumulate above and below the aromatic face and 
partial positive charge to accumulate around the periphery.25 This charge distribution is shown in 
Figure 10. As a result of this quadruple moment, pi electron repulsion dominates in the face-face 
geometry and attraction between the pi electrons and sigma framework dominates in the edge-
face and offset face geometries.25 Thus, the edge-face geometry and offset face geometry are 
isoenergetic and are lower in energy than the face-face geometry.25,26 
Face-face  Edge-face  Offset face  
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There is controversy over the effect that substituents have on both the geometry and 
magnitude of pi stacking interactions. According to the Hunter-Saunders model, pi stacking 
interactions between an electron-withdrawing substituted benzene and benzene and pi stacking 
interactions between an electron-donating substituted benzene and benzene both adopt the face-
face geometry.25 Despite congruence in the geometry of pi stacking interactions, the magnitude 
of pi stacking interactions in these two scenarios is vastly different. The presence of an electron-
withdrawing group decreases the quadruple moment of the substituted benzene, thereby reducing 
pi electron repulsion between the substituted molecule and benzene and increasing the magnitude 
of pi stacking interactions. On the other hand, the presence of an electron-donating group 
increases the quadruple moment of the substituted benzene, thereby increasing pi electron 
repulsion between the substituted molecule and benzene and decreasing the magnitude of pi 
stacking interactions.25 
Caution must be taken when solely relying on electrostatics to determine the geometry 
and magnitude of pi stacking interactions. In contrast to the Hunter-Saunders model, an ab initio 
study by Sinnokrot and Sherrill found all substituted benzene dimers to have greater pi stacking 
interactions than unsubstituted benzene dimers, regardless of the electron withdrawing or 
electron donating properties of the substituents.26 The substituent effects seem to be additive for 
face-face pi stacking configurations.27 These findings suggest that other factors besides 
electrostatics, such as hydrogen bonding and the hydrophobic effect, affect pi stacking 
interactions.  
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To determine the relative importance of 
electrostatics in pi-stacking interactions, Martinez and 
Iverson examined the effect of solvent polarity on the 
degree of pi stacking between 1,5-dialkoxynaphthalene 
(DAN) and 1,4,5,8-naphthalenediimide (NDI), whose 
structures are shown in Figure 11.28  The researchers 
theorized that increasing solvent polarity would increase 
the extent of pi stacking interactions in isolated DAN and 
isolated NDI solutions. Because the molecules in solution were not electrostatically compatible, 
the hydrophobic effect was believed to drive pi stacking interactions. In a 1:1 DAN:NDI mixture, 
both electrostatics and the hydrophobic effect had to be considered as drivers of pi stacking 
interactions because the electron rich DAN electrostatically complemented the electron poor 
NDI. If intermolecular electrostatic interactions dominated, the extent of pi stacking interactions 
should increase with decreasing solvent polarity. If the hydrophobic effect dominated, the extent 
of pi stacking interactions should increase with increasing solvent polarity. Thus, the changes in 
DAN/NDI pi stacking interactions that resulted from changes in solvent polarity was dependent 
on the relative importance of electrostatics and the hydrophobic effect in driving such 
interactions. As shown in Figure 12, the researchers found a correlation between increasing 
solvent polarity and increasing strength of pi interaction, indicating that the hydrophobic effect 









Figure 11. 1,5-dialkoxynaphthalene 
(DAN) and 1,4,5,8-naphthalenediimide 
(NDI) used by Martinez and Iverson.  
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Although pi stacking interactions 
were primarily driven by the hydrophobic 
effect, the effectiveness of the hydrophobic 
effect in generating pi stacking interactions 
depended upon the geometry of such 
interaction, which in turn was driven by 
electrostatic complementarity. For example, 
the pi stacking interactions for DAN/NDI 
were not the same as those for NDI/NDI or 
DAN/DAN despite the same solvent 
conditions. Since DAN/NDI adopts an 
alternating face-face geometry, solvation effects bury the largest amount of non-polar surface 
area compared to the offset-face and edge-face geometries seen in NDI/NDI and DAN/DAN 
complexes, respectively.28 Overall, it appears that electrostatics determine the type of pi stacking 
interaction and solvent polarity determines the extent or strength of the interaction.28  
Due to the lack of control in specifying the geometry of pi stacking interactions and the 
solvent dependence of such interactions, the deliberate use of pi stacking interactions in 
asymmetric synthesis has been a relatively recent trend.  To examine the influence of pi stacking 
interactions in controlling the stereochemistry of chiral glycosylates, Whitesell performed a 
variety of ene reactions using modified 8-phenylmenthol chiral catalysts, which are shown in 
Figure 13.29 As shown in Figure 13, the inclusion of a phenyl group within the catalyst increased 
the diastereoselectivity of the reaction.29 Although steric factors had some effect on this trend, 
factors are the most energetically important for NDI–DAN
stacking in strongly interacting solvents, such as water. Based on
previous discussions, the most important possibilities to be
considered are their complementary electrostatics (the Hunter–
Sanders framework and/or direct int raction betwe n substitu-
ents) or solvation/desolvation effects (i.e. the hydrophobic effect
in polar solvents).
These effects are expected to behave differently as solvent
polarity is systematically changed from non-polar to polar
solvents. In particular:
1. Electrostatic interactions are expected to increase in non-
polar (low dielectric) solvents, but decreas in more polar (high
dielectric) solvents. If electrostatics dominate, there should be
a significant difference between the highly favoured DAN–NDI
aromatic donor–acceptor interactions and the less favoured
DAN–DAN or NDI–NDI self-stacking.
2. Solvation/desolvation effects, on the other hand, are
expected to increase dramatically with increasing polarity, in
contrast to the trend expected for electrostatic interactions. If
solvation/desolvation effects alone drive association, then in
polar solvents, such as water, association should depend
primarily on the buried contact surface area. To a first approx-
imation, there should be little difference between DAN–NDI
alternating stacking and DAN–DAN or NDI–NDI self-stack-
ing, assuming that the units stack in a face-centred fashion.
The bottom line here is tha it should th refore be possible to
identify the most significant energetic driving force for the
stacking of NDI and DAN by synthesizing broadly soluble
derivatives and measuring their interactions in solvents of
various polarities.
Table 1 lists the previously reported NMR studies by our lab
on the interactions of DAN, NDI, and 1 : 1 DAN:NDI mixtures
in solvents of various polarities. When plotted using the polarity
parameter ET(30), the data reveal a striking correlation between
an increasing strength of interaction and increasing solvent
polarity (Fig. 3). In other words, the dominant energetic inter-
action appears to be solvation/desolvation, i.e. the hydrophobic
effect. Notably, the line fit for hydrogen-bonding solvents has
a somewhat steeper slope than the other solvents, indicating that
solvent hydrogen bonding is particularly important for aromatic
stacking.
Nevertheless, electrostatics, either polar/pi or direct substit-
uent interactions, must also be playing a role. There is an order of
magnitude difference between the Ka of the lowest energy
DAN:DAN pair, which adopts an edge-to-face T-shaped
arrangement in the solid state, and the NDI:NDI dimer
arrangement, which adopts an off-centre parallel stacking
geometry in the solid state. The Ka of the NDI:DAN dimer is ten
times greater still3 and exhibits an alternating, face-centred
parallel stacking geometry in the solid state. Note that the solid
state structural trends, and by inference the geometries in solu-
tion, are exactly those predicted from electrostatic considerations
in the sense that only the DAN:NDI dimer is expected to be face-
center stacked.
The picture that emerges from these studies is that the driving
force for these ar matic associations in polar solvents is
primarily derived from desolvation effects (the hydrophobic
effect), but the extent of this driving force is dictated by the
geometry of association (i.e. amount of buried hydrophobic
surface area), which, in turn, is dependent on electrostatic
complementarity. In particular, the DAN–NDI electrostatics are
complementary in a face-centred, stacked arrangement that
buries maximum non-polar surface area, thereby leading to the
maximum observed association. The NDI–NDI pair has
complementary electrostatics in the off-centred stacking mode
that is observed in the solid state and this geometry qualitatively
predicts an intermediate level of buried hydrophobic surface
area, thus explaining the intermediate association that is seen.
The DAN–DAN pair has electrostatics that predict an edge-to-
face interaction also seen in the solid state. Such a geometry for
the DAN–DAN pair buries the least hydrophobic surface area
and qualitatively predicts the lowest association constant,
consistent with our results.
The polar protic solvents exhibit a steeper slope in Fig. 3
compared to nonpolar and aprotic solvents. It is important to
Table 1 Self-association constants for mixtures of DAN and NDI mixtures calculated using HOSTEST dimerization models. Free energy values





1 CDCl3 (1) (1) 2 " <0.5
2 acetone-d6 1 " <0.5 1 " <0.5 8 " <0.5
3 DMSO-d6 1 " 1 2 " <0.5 3 " <0.5
4 CD3CN 1 " 1 3 " <0.5 11 " <0.5
5 CD3OD 1 " <0.5 8 " <0.5 30 " <0.5
6 3 : 1 CD3OD/D2O 1 " <0.5 15 " <0.5 63 " 2
7 1 : 1 CD3OD/D2O 2 " <0.5 28 " 2 254 " 41
8 1 : 3 CD3OD/D2O 10 " 2 101 " 28 952 " 64
9 D2O 20 " 4 245 " 101 2045 " 63
Fig. 3 The polarity parameter ET(30)
128 plotted against calculated free
energy change values for the 1 : 1 donor:acceptor complexes measured in
Table 1; 1–9 represent the experimental solvent conditions from the table.





























Figure 12. Energetic favorability of pi stacking 
interactions between DAN and NDI as a function of 
solvent pola ity, as assessed by ET(30) value. The blue 
dots represent the following nonpolar aprotic solvents: 1= 
CDCl3, 2 = d6-acetone, 3 = d6-DMSO, 4 = CD3CN. The 
red dots represent the following polar protic solvents: 5 = 
CD3OD, 6 = 3:1 CD3OD/D2O, 7 = 1:1 CD3OD/D2O, 8 = 
1:3 CD3OD/D2O, 9 = D2O. Reprinted from Martinez and 
Iverson.   
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saturation of the phenyl greatly reduced the stereoselectivity of the ene reaction, suggesting that 
pi stacking interactions facilitated stereoselectivity.29,30  
	  
Figure 13.	  The effect of various substituents on 8-phenylmenthol in the stereoselective synthesis 
of chiral glyoxylates. The diastereomeric excess (de) is a measure of the stereoselectivity of the 
reaction. Adapted from D’Attilio.	  
1.2.2.1 Pi Stacking Chiral Auxiliaries  
Based upon the ability of pi stacking interactions to generate stereoselectivity, pi stacking 
chiral auxiliaries were substituted for methyl acrylate in the sixth step of the synthesis of T-06. 
As shown in Figure 14, mandelate acrylate was the first pi stacking chiral auxiliary used. We 
expected a pi stacking interaction to form between the benzene portion of the mandelate acrylate 
B and the fluoroaniline portion of the T-07 carbanion 5.i, as shown in the inset of Figure 14. This 
pi stacking interaction was expected to favor the formation of a major and minor T-06 mandelate 
ester 6.B diastereomer. After separating the diastereomers via column chromatography, they 
could be base hydrolyzed to form a major and minor T-06 7 enantiomer.  
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Figure 14. Michael addition of T-07 5 to mandelate acrylate B generates T-06 mandelate ester 
6.B diastereomers. The hypothesized transition state shown in the inset is characterized by a pi 
stacking interaction between the benzene portion of the mandelate acrylate B and the 
fluoroaniline portion of T-07 carbanion 5.i.  
Naphthalene acrylate C was the second pi stacking chiral auxiliary used to make the 
Michael addition stereoselective. As shown in Figure 15, we expected the naphthalene portion of 
the naphthalene acrylate C to form a pi stacking interaction with the isoquinoline portion of the 
T-07 carbanion 5.i. This pi stacking interaction was expected to favor the formation of a major 
and minor T-06 naphthalene ester 6.C diastereomer that could be separated via column 
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Figure 15.	  Michael addition of T-07 5 to naphthalene acrylate C generates T-06 naphthalene 
ester 6.C diastereomers. The hypothesized transition state shown in the inset is characterized by 
a pi stacking interaction between the naphthalene portion of the naphthalene acrylate C and the 
isoquinoline portion of the T-07 carbanion 5.i. 
1.2.2.2 Pi Stacking Catalyst  
In addition to using pi stacking chiral auxiliaries, a chiral catalyst was used to make the 
Michael addition stereospecific. As shown in Figure 16, dinaphthyl pyrrolidine methanol was 
used in the Michael addition of T-07 5 to methyl acrylate. We expected the naphthalene moieties 
within the catalyst to form pi stacking interactions with the T-07 carbanion 5.i. These pi stacking 
interactions were expected to mediate the formation of a major and minor T-06 methyl ester 6 
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enantiomer. 
	  
Figure 16. Dinaphthyl pyrrolidine methanol used a catalyst to generate the stereoselective 
Michael addition of T-07 5 to methyl acrylate.  
1.3 Project Goals  
The ultimate goal is to generate a stereospecific Michael addition that can be used to synthesize 
T-06 6 in enantiomeric excess. My specific project goals are to:  
1) Synthesize T-07 5, mandelate acrylate B, and naphthalene acrylate C.  
2) Perform the isobornyl acrylate modified, mandelate acrylate modified, naphthalene 
acrylate modified, and dinaphthyl pyrrolidine methanol modified Michael additions.  
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2. RESULTS AND DISCUSSION  
Chiral auxiliaries and a chiral catalyst were used to make the Michael addition 
stereoselective. The types of chiral auxiliaries and chiral catalyst used are shown in Table 1. In 
this section, the synthesis and success of the chiral auxiliaries and chiral catalyst at generating a 
stereoselective Michael addition are described. 
Table 1. Chiral auxiliaries and catalyst used to make a stereoselective Michael addition. 
Chiral Auxiliaries Steric Isobornyl acrylate:  
 
Pi stacking Mandelate acrylate: 
 
Naphthalene acrylate:  
 




2.1 Chiral Auxiliaries  
  As shown in Table 1, three different chiral auxiliaries were used to make the Michael 
addition stereoselective. The first auxiliary, isobornyl acrylate, was expected to generate 
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latter two auxiliaries, mandelate acrylate and naphthalene acrylate, were expected to generate 
stereoselectivity through the formation of pi stacking interactions and are herein referred to as pi 
stacking chiral auxiliaries. The success of the steric chiral auxiliary and the pi stacking chiral 
auxiliaries at generating stereoselectivity is detailed below. 
2.1.1 Steric Auxiliaries  
Isobornyl acrylate was used in the Michael addition as a steric chiral auxiliary. The 
Michael addition with isobornyl acrylate is shown in Scheme 1 and a more detailed reaction 
	  
Scheme 1. Michael addition of T-07 5 to isobornyl acrylate A generates T-06 isobornyl ester 6.A 
diastereomers.  
mechanism is shown in Figure 17. As shown in Figure 17, deprotonation of T-07 5 by the 
carbonate ion generated a T-07 carbanion intermediate 5.i. We expected the steric bulk of the 
isobornyl moiety within the acrylate to force the T-07 carbanion 5.i to attack the β-carbon of the 
isobornyl acrylate A with facial selectivity. As shown in the inset of Figure 17, the preferred 
transition state conformation is one in which the bulk of the isobornyl group is positioned away 
from the T-07 carbanion 5.i. This preferred arrangement minimizes steric crowding and aligns 
the nucleophilic T-07 carbanion 5.i directly below the electrophilic β-carbon of the isobornyl 
acrylate A, thereby favoring nucleophilic attack from the underside rather than the topside of the 
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diastereomer 6.A.1 and a minor T-06 isobornyl ester diastereomer 6.A.2, as shown in Figure 17.
	  
Figure 17. Steric interactions between the T-07 carbanion 5.i and the isobornyl acrylate A are 
expected to generate the stereoselective Michael addition of T-07 5 to isobornyl acrylate A, 
resulting in a major T-06 isobornyl ester diastereomer 6.A.1 and a minor T-06 isobornyl ester 
diastereomer 6.A.2. 
The T-06 isobornyl ester 6.A was isolated from reaction side products using silica gel 
flash chromatography. The 1H-NMR spectrum of T-07, provided in Appendix 7, contains a 
doublet at δ5.6 ppm and a doublet at δ5.9 ppm. Both of these doublets correspond to the proton 
on the chiral carbon of T-07. The absence of these peaks in the 1H-NMR spectrum of the T-06 
isobornyl ester 6.A, shown in Figure 18, suggests that the tertiary chiral center of T-07 5 was 
converted to the quaternary chiral center of the T-06 isobornyl ester 6.A. The 1H-NMR spectrum 
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protons. These chemical shifts are typical of protons on carbon atoms that are adjacent to esters 
and amides,31 suggesting that T-07 5 added at the β-carbon of the isobornyl acrylate A to 
produce the T-06 isobornyl ester 6.A 
 
Figure 18. 1H-NMR spectrum of T-06 isobornyl ester 6.A in CDCl3: δ0.8-2.0 ppm (multiple 
peaks, 17H, 9H from methyl groups within isobornyl moiety, 8H from isobornyl moiety), δ2.3 
ppm (m, 1H on alkyl chain), δ2.7 ppm (m, 3H on alkyl chain), δ3.8 ppm (s, 3H, methoxy 
substituent on the m-anisidine ring), δ6.2 ppm (s, 1H, H in between the methoxy substituent and 
pyrrolidine ring of m-anisidine ring), δ6.6 ppm (d, 1H, H on m-anisidine ring), δ7.2-8.0 ppm (m, 
9H, 1H on m-anisidine ring, 4H within fluorobenzene, 4H within benzene ring of isoquinoline 
moiety), δ8.6 ppm (s, 1H, H of amide within isoquinoline side chain), δ9.1 ppm (s, 1H, H within 
nitrogen-containing ring of isoquinoline moiety), δ9.3 ppm (s, 1H, H within nitrogen-containing 
ring of isoquinoline moiety).  
 
Although silica gel flash column chromatography was successful at separating the T-06 
isobornyl ester 6.A from reaction side products, it was unsuccessful at separating the two T-06 
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(HPLC) was used to separate the diastereomers. The chromatogram from the chiral HPLC 
column, shown in Figure 19, features three major peaks at minutes 6.012, 8.859, and 9.577. This 
result was surprising because the fixed stereochemistry of the isobornyl acrylate meant that only 
two T-06 isobornyl ester diastereomers could be produced. If the isobornyl acrylate purchased 
from Sigma Aldrich was not enantiopure, however, four diastereomers could be produced. The 
purity of the isobornyl acrylate could not be determined with GC-MS or 1H-NMR spectroscopy. 	  
Identification of the peaks via 1H-NMR spectroscopy was unsuccessful because the small 
amount of product collected resulted in a small 1H-NMR signal. The reaction was repeated in 
order to generate more T-06 isobornyl ester 6.A. This would allow for a higher concentration of 
T-06 isobornyl ester 6.A to be used in 1H-NMR spectroscopy, thereby increasing the signal to 
noise ratio. When the reaction was repeated, however, none of the desired the T-06 isobornyl 
ester 6.A was produced. The origin of this unsuccessful trial has not yet been elucidated. As a 
wellesley college
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Figure 19.	  Chromatogram from T-06 isobornyl ester 6.A chiral HPLC column. The major peaks 
occurred at 6.012, 8.859, and 9.577 minutes 
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result, the HPLC peaks remained uncharacterized and the stereoselectivity of the reaction was 
not determined.  
2.1.2 Pi Stacking Auxiliaries  
The undetermined stereoselectivity of the Michael addition using the steric chiral 
auxiliary prompted the use of pi stacking chiral auxiliaries, as shown in Table 1. The two pi 
stacking chiral auxiliaries used were mandelate acrylate and naphthalene acrylate. The synthesis 
and success of each acrylate in generating a stereoselective Michael addition are detailed below.  
2.1.2.1 Mandelate Acrylate 
 As shown in Scheme 2, the mandelate acrylate B was synthesized from mandelate 
alcohol and acryloyl chloride through a 
nucleophilic acyl substitution reaction. 
The mass spectrum of the purified 
product, shown in Figure 20, is 
characterized by a molecular ion (M+) 
peak at 234 m/z, which corresponds to the molecular weight of the mandelate acrylate. The peak 
at 179 m/z and the peak at 161 m/z correspond to the loss of the α, β unsaturated ketone portion 
of the acrylate and the loss of the α, β unsaturated ester portion of the acrylate, respectively, 
during fragmentation of the molecular ion, further confirming the formation of the mandelate 











Scheme 2. Synthesis of mandelate acrylate B. 
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Figure 20. Electron impact-mass spectrum of purified mandelate acrylate B. The M+ peak occurs 
at 234 m/z.  
The 1H-NMR spectra of acryloyl chloride, the mandelate alcohol, and the mandelate 
acrylate are overlaid in Figure 21. The peak highlighted by the dashed red line at δ3.5 ppm in the 
1H-NMR spectrum of the mandelate alcohol corresponds to the hydroxyl proton. The absence of 
this peak in the 1H-NMR spectrum of the mandelate acrylate B suggests that the oxygen of the 
mandelate alcohol reacted with acryloyl chloride to form the ester. Furthermore, the peak 
highlighted by the dashed blue line at δ5.2 ppm in the 1H-NMR spectrum of the mandelate 
alcohol and δ6.0 ppm in the 1H-NMR spectrum of the mandelate acrylate corresponds to the 
proton attached to the chiral center. The δ0.8 ppm shift of this peak confirms the successful 
conversion of the alcohol to the ester.33 Individual 1H-NMR spectrum of acryloyl chloride, 
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Figure 21.	  Overlaid 1H-NMR spectra of acryloyl chloride (top), mandelate alcohol (middle), and 
mandelate acrylate B (bottom). The dashed blue and red lines show the chemical shift of the 
protons highlighted in blue and red, respectively, within the structures shown on the right. 1H-
NMR spectrum of acryloyl chloride in CDCl3: δ6.2 ppm (d, 1 vinylic H that is β to the carbonyl 
and cis to the vinylic H that is α to the carbonyl), δ6.3 ppm (t, 1 vinylic H α to the carbonyl), 
δ6.6 ppm (d, 1 vinylic H β to the carbonyl and trans to the vinylic H α to the carbonyl). 1H-NMR 
spectrum of mandelate alcohol in CDCl3: δ1.3 ppm (t, 3H, CH3 within the ethoxy group), δ3.5 
ppm (s, 1H of the alcohol), δ4.1-4.4 ppm (m, 2H, CH2 within ethoxy group), δ5.2 ppm (s, 1H α 
to the benzene moiety), δ7.3-7.5 ppm (m, 5H on the benzene moiety). 1H-NMR spectrum of 
mandelate acrylate in CDCl3: δ1.2 ppm (t, 3H, CH3 within the ethoxy group), δ4.2 ppm (q, 2H, 
CH2 within ethoxy group), δ5.9 ppm (d, 1 vinylic H that is β to the carbonyl and cis to the 
vinylic H that is α to the carbonyl), δ6.0 ppm (s, 1H α to the benzene moiety), δ6.2 ppm (q, 1 
vinylic H α to the benzene moiety), δ6.5 ppm (d, 1 vinylic H that is β to the carbonyl and trans to 
the vinylic H that is α to the carbonyl), δ7.3-7.6 ppm (m, 5H on benzene). 
The Michael addition with mandelate acrylate B is shown in Scheme 3 and a more 
detailed reaction mechanism is shown in Figure 22. As shown in Figure 22, we expected the 
benzene portion of the mandelate acrylate B to form a pi stacking interaction with the 
fluoroaniline portion of the T-07 carbanion 5.i. This pi stacking interaction, highlighted in red in 
Figure 22, was expected to force the T-07 carbanion 5.i to attack the β-carbon of the mandelate 
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major T-06 mandelate ester diastereomer 6.B.1 and a minor T-06 mandelate ester diastereomer 
6.B.2, as shown in Figure 22.  
  
Figure 22. The pi stacking interaction between the fluoroaniline moiety of the T-07 carbanion 5.i 
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the stereoselective Michael addition of T-07 5 to the mandelate acrylate B, resulting in a major 
T-06 mandelate ester diastereomer 6.B.1 and a minor T-06 mandelate ester diastereomer 6.B.2. 
The T-06 mandelate ester diastereomers 6.B.1 and 6.B.2 were partially separated from 
each other using silica gel flash chromatography. The 1H-NMR spectrum of the diastereomer that 
eluted first, which is herein referred to as the fast diastereomer, is shown in Figure 23, and the 
1H-NMR spectrum of the diastereomer that eluted more slowly, which is herein referred to as the 
slow diastereomer, is shown in Figure 24. It is important to note that the 1H-NMR spectrum of 
each T-06 mandelate ester 6.B diastereomer is slightly polluted with the other diastereomer 
because of inefficient purification via column chromatography. As a result of these impurities, 
the peaks at δ6.0 ppm and δ6.3 ppm in Figure 23 and the peaks at δ5.8 ppm and δ6.2 ppm in 
Figure 24 exist as lopsided doublets rather than singlets. Since these lopsided doublets would 
exist as singlets if the diastereomers were completely pure, these peaks are referred to as singlets. 
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Figure 23. 1H-NMR spectrum of the fast T-06 mandelate ester diastereomer in CDCl3: δ1.2 ppm 
(t, 3H on the methyl of the ethoxy group), δ2.3-2.8 ppm (m, 4H on alkyl chain), δ3.7 ppm (m, 
3H, methoxy substituent on the m-anisidine ring), δ4.2 ppm (q, 2H, CH2 within ethoxy group), 
δ6.0 ppm (s, 1H α to the benzene within the mandelate moiety), δ6.3 ppm (s, 1H, H in between 
the methoxy substituent and pyrrolidine ring of m-anisidine ring), δ6.7 ppm (do, 1H, H on m-
anisidine ring), δ7.2-8.2 ppm (m, 14H, 1H on m-anisidine ring, 4H within fluorobenzene, 4H 
within benzene ring of isoquinoline moiety, 5H on benzene within mandelate moiety), δ8.6 ppm 
(s, 1H, H of amide within isoquinoline side chain), δ9.1 ppm (s, 1H, H within nitrogen-
containing ring of isoquinoline moiety), δ9.3 ppm (s, 1H, H within nitrogen-containing ring of 
isoquinoline moiety). The blue lines indicate peaks that are unique to the fast T-06 mandelate 
ester diastereomer.  
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Figure 24. 1H-NMR spectrum of the slow T-06 mandelate ester diastereomer in CDCl3: δ1.2 
ppm (t, 3H on the methyl of the ethoxy group), δ2.0-2.3 ppm (m, 1H on alkyl chain), δ2.3-2.8 
ppm (m, 3H on alkyl chain), δ3.7 ppm (m, 3H, methoxy substituent on the m-anisidine ring), 
δ4.2 ppm (q, 2H, CH2 within ethoxy group), δ5.8 ppm (s, 1H α to the benzene within the 
mandelate moiety), δ6.2 ppm (s, 1H, H in between the methoxy substituent and pyrrolidine ring 
of m-anisidine ring), δ6.7 ppm (d, 1H, H on m-anisidine ring), δ7.2-8.2 ppm (m, 14H, 1H on m-
anisidine ring, 4H within fluorobenzene, 4H within benzene ring of isoquinoline moiety, 5H on 
benzene within mandelate moiety), δ8.6 ppm (s, 1H, H of amide within isoquinoline side chain), 
δ9.1 ppm (s, 1H, H within nitrogen-containing ring of isoquinoline moiety), δ9.3 ppm (s, 1H, H 
within nitrogen-containing ring of isoquinoline moiety). The red lines indicate peaks that are 
characteristic of the slow T-06 mandelate ester diastereomer.  
 
The absence of a doublet at δ5.6 ppm and a doublet at δ5.9 ppm, both of which are 
characteristic of the proton on the chiral carbon of T-07 5, in the 1H-NMR spectra shown in 
Figure 23 and Figure 24 suggest that the tertiary chiral center of T-07 5 was converted to the 
quaternary chiral center of the T-06 mandelate ester 6.B diastereomers. The 1H-NMR spectra 
shown in Figure 23 and Figure 24 also feature peaks between δ2.0 ppm and δ3.0 ppm that 
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integrate for four protons. These chemical shifts are typical of protons on carbon atoms adjacent 
to esters and amides, suggesting that T-07 5 added at the β-carbon of the mandelate acrylate B.31  
Despite the contamination of each diastereomer’s 1H-NMR spectrum with the other 
diastereomer, it is clear that the 1H-NMR spectra of the diastereomers differ in the exact location 
of the singlet slightly to the left of δ6.0 ppm and the singlet slightly to the right of δ6.0 ppm. The 
location of these singlets is highlighted by the blue lines at δ6.0 ppm and δ6.3 ppm in Figure 23 
and by the red lines at δ5.8 ppm and δ6.2 ppm in Figure 24. The intensities of the peaks 
highlighted by the blue lines in Figure 23 and by the red lines in Figure 24 were used to quantify 
the relative abundance of each diastereomer within a sample containing both diastereomers. The 
1H-NMR spectrum of the sample containing both diastereomers is shown in Figure 25. The 
peaks characteristic of the fast diastereomer and the peaks characteristic of the slow diastereomer 
are highlighted with blue and red lines, respectively. 
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Figure 25. 1H-NMR spectrum of a mixture of the T-06 mandelate ester diastereomers in CDCl3: 
δ1.2 ppm (t, 6H, 3H on the methyl of the ethoxy group of the fast diastereomer and 3H on the 
methyl of the ethoxy group of the slow diastereomer), δ2.0-2.3 ppm (m, 2H, 1H on alkyl chain of 
the fast diastereomer, 1H on alkyl chain of the slow diastereomer), δ2.3-2.8 ppm (m, 6H, 3H on 
alkyl chain of the fast diastereomer, 3H on alkyl chain of the slow diastereomer), δ3.7 ppm (m, 
6H, 3H of methoxy substituent on the m-anisidine ring of the fast diastereomer, 3H of methoxy 
substituent on the m-anisidine ring of the slow diastereomer), δ4.2 ppm (q, 4H, 2H of CH2 within 
ethoxy group of the fast diastereomer, 2H of CH2 within ethoxy group of the slow diastereomer), 
δ5.8 ppm (s, 1H α to the benzene within the mandelate moiety of the slow diastereomer), δ6.0 
ppm (s, 1H α to the benzene within the mandelate moiety of the fast diastereomer), δ6.2 ppm (s, 
1H, H in between the methoxy substituent and pyrrolidine ring of m-anisidine ring of the slow 
diastereomer), δ6.3 ppm (s, 1H, H in between the methoxy substituent and pyrrolidine ring of m-
anisidine ring of the fast diastereomer), δ6.7 ppm (d, 2H, 1H on m-anisidine ring of fast 
diastereomer, 1H on m-anisidine ring of slow diastereomer), δ7.2-8.2 ppm (m, 28H, (1H on m-
anisidine ring, 4H within fluorobenzene, 4H within benzene ring of isoquinoline moiety, 5H on 
benzene within mandelate moiety) of fast diastereomer, (1H on m-anisidine ring, 4H within 
fluorobenzene, 4H within benzene ring of isoquinoline moiety, 5H on benzene within mandelate 
moiety) of slow diastereomer), δ8.6 ppm (s, 2H, 1H of amide within isoquinoline side chain of 
fast diastereomer, 1H of amide within isoquinoline side chain of slow diastereomer), δ9.1 ppm 
(s, 2H, 1H within nitrogen-containing ring of isoquinoline moiety of fast diastereomer, 1H within 
nitrogen-containing ring of isoquinoline moiety of slow diastereomer), δ9.3 ppm (s, 2H, 1H 
within nitrogen-containing ring of isoquinoline moiety of fast diastereomer, 1H within nitrogen-
containing ring of isoquinoline moiety of slow diastereomer). The blue lines indicate peaks that 
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are characteristic of the fast T-06 mandelate ester diastereomer whereas the red lines indicate 
peaks that are characteristic of the slow T-06 mandelate ester diastereomer. 
As shown in Figure 25, the intensities of the peaks highlighted by the blue lines are roughly 
equal to the intensities of the peaks highlighted by the red lines. By measuring the height of the 
highlighted peaks, the ratio of the fast diastereomer to the slow diastereomer was determined to 
be 48:52, implying that the Michael addition with mandelate acrylate B was not stereoselective.  
2.1.2.2 Naphthalene Acrylate  
  The lack of stereoselectivity in the mandelate acrylate Michael addition was attributed to 
the relatively small area within the mandelate acrylate that was capable of forming pi stacking 
interactions. To address this problem, naphthalene acrylate was used in the Michael addition 
because it has a more extended pi system. We expected the naphthalene acrylate to form more pi 
stacking interactions than the mandelate acrylate and as a result, enhance the stereoselectivity of 
the Michael addition.  
 As shown in Scheme 4, the naphthalene acrylate C was synthesized from naphthalene 
alcohol and acryloyl chloride through a 
nucleophilic acyl substitution reaction. 
The mass spectrum of the purified product, 
shown in Figure 26, is characterized by a 
molecular ion (M+) peak at 226 m/z, which 







Scheme 4. Synthesis of naphthalene acrylate C. 
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Figure 26. Electron impact-mass spectrum of purified naphthalene acrylate C. The M+ peak 
occurs at 226 m/z. 
The 1H-NMR spectra of acryloyl chloride, the naphthalene alcohol, and the naphthalene 
acrylate are overlaid in Figure 27. The peak highlighted by the dashed red line at δ2.1 ppm in the 
1H-NMR spectrum of naphthalene alcohol corresponds to the hydroxyl proton. The absence of 
this peak in the 1H-NMR spectrum of the naphthalene acrylate suggests that the oxygen of the 
naphthalene alcohol reacted with acryloyl chloride to form the ester. Furthermore, the peak 
highlighted by the dashed blue line at δ5.1 ppm in the 1H-NMR spectrum of the mandelate 
alcohol and δ6.2 ppm in the 1H-NMR spectrum of the mandelate acrylate corresponds to the 
proton attached to the chiral center. The δ1.1 ppm shift of this peak confirms the successful 
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Figure 27. Overlaid 1H-NMR spectra of acryloyl chloride (top), naphthalene alcohol (middle), 
and naphthalene acrylate (bottom). The dashed blue and red lines show the chemical shift of the 
protons highlighted in blue and red, respectively, within the structures shown on the right. 1H-
NMR spectrum of acryloyl chloride in CDCl3: δ6.2 ppm (d, 1 vinylic H β to the carbonyl and cis 
to the vinylic H α to the carbonyl), δ6.3 ppm (t, 1 vinylic H α to the carbonyl), δ6.6 ppm (d, 1 
vinylic H β to the carbonyl and trans to the vinylic H α to the carbonyl). 1H-NMR spectrum of 
naphthalene alcohol in CDCl3: δ1.6 ppm (d, 3H of methyl), δ2.1 ppm (broad s, 1H of alcohol), 
δ5.1 ppm (q, 1H α to the methyl), δ7.5-7.9 pm (two m, 7H on the naphthalene). 1H-NMR 
spectrum of naphthalene acrylate in CDCl3: δ1.8 ppm (d, 3H on methyl), δ5.7 ppm (d, 1 vinylic 
H β to the carbonyl and trans to the vinylic H that is α to the carbonyl), δ6.2 ppm (m, 2H, 1 
vinylic H α to the carbonyl, 1H α to the methyl), δ6.4 ppm (d, 1 vinylic H that is β to the 
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 The Michael addition with naphthalene acrylate is shown in Scheme 5 and a more 
detailed reaction mechanism is shown in Figure 28.
	  
Scheme 5. Michael addition of T-07 5 to naphthalene acrylate C generates T-06 naphthalene 
ester 6.C diastereomers.  
As shown in Figure 28, we expected the naphthalene portion of the naphthalene acrylate C to 
form a pi stacking interaction with the isoquinoline portion of the T-07 carbanion 5.i. This pi 
stacking interaction, highlighted in red, was expected to force the T-07 carbanion 5.i to attack the 
β-carbon of the naphthalene acrylate C with facial selectivity. Such preferential nucleophilic 
attack was believed to generate a major T-06 naphthalene ester diastereomer 6.C.1 and a minor 
























	   44 
	  
Figure 28. The pi stacking interaction between the isoquinoline moiety of the T-07 carbanion 5.i 
and the naphthalene moiety of the naphthalene acrylate C, highlighted in red, is expected to 
generate the stereoselective Michael addition of T-07 5 to naphthalene acrylate C, resulting in 
the formation of a major T-06 naphthalene ester diastereomer 6.C.1 and a minor T-06 
naphthalene ester diastereomer 6.C.2.  
The T-06 naphthalene ester 6.C was isolated from the other products using silica gel flash 
column chromatography. The 1H-NMR spectrum of the T-06 naphthalene ester 6.C is shown in 
Figure 29. The absence of a doublet at δ5.6 ppm and a doublet at δ5.9 ppm, both of which are 
characteristic of the proton on the chiral carbon of T-07 5, in the 1H-NMR spectrum shown in 
Figure 29 suggests that the tertiary chiral center of T-07 5 was converted to the quaternary chiral 
center of the T-06 naphthalene ester 6.C. The 1H-NMR spectrum shown in Figure 29 also 
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shifts are typical of protons on carbon atoms that are adjacent to esters and amides, suggesting 
that T-07 5 added at the β-carbon of the naphthalene acrylate C.31  
	  
Figure 29. 1H-NMR spectrum of T-06 naphthalene ester 6.C in CDCl3 prior to HPLC 
purification: δ1.8 ppm (d, 3H of methyl group within naphthalene moiety), δ2.3 ppm (m, 1H on 
alkyl chain), δ2.7 ppm (m, 3H on alkyl chain), δ3.8 ppm (s, 3H, methoxy substituent on the m-
anisidine ring), δ6.1 ppm (m, 1H α to the methyl group within the naphthalene moiety), δ6.2 ppm 
(s, 1H, H in between the methoxy substituent and pyrrolidine ring of m-anisidine ring), δ6.6 ppm 
(d, 1H, H on m-anisidine ring), δ7.2-8.0 ppm (m, 9H, 1H on m-anisidine ring, 4H within 
fluorobenzene, 4H within benzene ring of isoquinoline moiety), δ8.4 ppm (s, 1H, H of amide 
within isoquinoline side chain), δ9.1 ppm (s, 1H, H within nitrogen-containing ring of 
isoquinoline moiety), δ9.3 ppm (s, 1H, H within nitrogen-containing ring of isoquinoline 
moiety).  
 
Although silica gel flash column chromatography was successful at separating the T-06 
naphthalene ester diastereomers 6.C from reaction side products, it was unsuccessful at 
separating the T-06 naphthalene ester diastereomers 6.C.1 and 6.C.2 from each other. Chiral 
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shown in Figure 30, features two significant peaks at 7.176 minutes and 14.596 minutes. 
 
Figure 30. Chromatogram from T-06 naphthalene ester 6.C chiral HPLC column. The major 
peaks occurred at 7.176 minutes and 14.596 minutes.  
Ideally, the compounds that eluted at 7.176 and 14.596 minutes would have been 
characterized with both 1H-NMR spectroscopy and mass spectrometry. The eluents could not be 
characterized with 1H-NMR spectroscopy because the small amount of product collected 
generated a small 1H-NMR signal. The reaction was repeated in order to generate more T-06 
naphthalene ester 6.C. This would allow for a higher concentration of T-06 naphthalene ester 
6.C to be used in 1H-NMR spectroscopy, thereby increasing the signal to noise ratio. When the 
reaction was repeated, however, none of the desired T-06 naphthalene ester 6.C was produced. 
The origin of this unsuccessful trial has yet to be elucidated.  
The two HPLC peaks can be confidently classified as the two T-06 naphthalene ester 
diastereomers based upon the 1H-NMR spectrum shown in Figure 29 and the mass spectra of the 
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compounds that eluted at 7.176 and 14.596 minutes, shown in Figure 31 and Figure 32, 
respectively.  
	  
Figure 31. Electrospray spray ionization-mass spectrum of the T-06 naphthalene ester 
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Figure 32. Electrospray spray ionization-mass spectrum of T-06 naphthalene ester diastereomer 
at minute 14.596. The [M+H]+ peak occurs at 654.2 m/z. 
Both of these mass spectra feature a peak at 654 m/z. This peak corresponds to the 
[M+H]+ peak. We speculate that the amines within each T-06 naphthalene ester 6.C diastereomer 
facilitated protonation of the compound, resulting in a [M+H]+ peak rather than an M+ peak in 
the ESI-MS shown in Figure 31 and Figure 32. The [M+H]+ peak agrees with the molecular 
weight of the T-06 naphthalene ester diastereomer, confirming the presence of T-06 naphthalene 
ester diastereomers within the HPLC peaks. The mass spectra in Figure 31 and Figure 32 cannot 
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7.176 minutes or the diastereomer occurring at 14.596 minutes. This limitation, coupled to the 
lack of a 1H-NMR spectrum for each HPLC peak, made it difficult to determine which T-06 
naphthalene ester 6.C diastereomer corresponded to which HPLC peak.  
The diastereomer identity of each HPLC peak was not needed to calculate the 
stereoselectivity of the reaction. The stereoselectivity of the reaction was determined two ways. 
First, the amount of product contained within each HPLC peak was measured by mass after 
manually collecting the fractions. Second, the area under each HPLC peak was calculated. The 
ratio of the diastereomer at minute 7 to the diastereomer at minute 14 was 60:40 by mass and 
49:51 by HPLC peak area. These results do not agree with each other. It is important to note that 
less than 0.001 g of each product was collected. Given the small amount of product collected, 
any impurity within or any solvent remaining in the sample will have significantly contributed to 
the recorded mass, making the diastereomeric ratio calculated by mass less reliable than the 
value from HPLC. The diastereomeric ratio calculated by HPLC peak area indicates that the 
Michael addition with naphthalene acrylate C was not stereoselective. 
2.2 Chiral Catalyst  
  The inability of the chiral auxiliaries to generate a stereoselective Michael addition 
prompted the use of a chiral catalyst. The chiral catalyst that was used was based upon the work 
of Lattanzi et al.34 Lattanzi et al. used dinaphthyl pyrrolidine methanol to stereoselectively add 
1,3-dicarbonyl compounds to nitroalkenes, as shown in Scheme 6. 	  
In addition to achieving a yield greater than 95%, the ratio of the major diastereomer produced to 
the minor diastereomer produced exceeded 90:1. The researchers attributed the observed 
stereoselectivity to the formation of pi stacking interactions and hydrogen bonding.  
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  The Michael addition of T-07 5 to methyl acrylate using the chiral catalyst is shown in 
Figure 33.   
	  
Figure 33. Dinaphthyl pyrrolidine methanol was expected to generate the stereoselective 
Michael addition of T-07 5 to methyl acrylate, resulting in a major T-06 methyl ester enantiomer 
6.1 and a minor T-06 methyl ester enantiomer 6.2. 
This Michael addition differs from the one performed by Lattanzi et al. in several ways. First, the 
T-07 carbanion 5.i is alpha to an amide and a carbonyl whereas the nucleophilic carbon in the 
dicarbonyl compound 2a is alpha to two carbonyls. The T-07 carbanion 5.i is stabilized through 


































































Scheme 6. Dinaphthyl pyrrolidine methanol 3b prompts the enantioselective Michael addition of 
the dicarbonyl compound 2a to the nitroalkene 1a. 
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provided by the two carbonyl groups alpha to the nucleophilic carbon in the dicarbonyl 
compound 2a. The reaction should not be substantially affected by the replacement of the 
dicarbonyl compound 2a with the T-07 carbanion because the nucleophile in both cases is 
resonance stabilized. Additionally, methyl acrylate is the electrophile in the Michael addition 
shown in Figure 33 whereas nitroalkene is the electrophile in the Michael addition shown in 
Scheme 6. The reaction should not be substantially affected by the replacement of the 
nitroalkene 1a with methyl acrylate because both the nitro group within the nitroalkene 1a and 
the carbonyl group within methyl acrylate are electron withdrawing, resulting in an electrophilic 
β-carbon that is susceptible to nucleophilic attack. Overall, these differences were not expected 
to alter the stereoselectivity achieved by the catalyst. 
  As shown in Figure 33, T-07 5 was mixed with the dinaphthyl pyrrolidine methanol 
catalyst and potassium carbonate. The catalyst was believed to form stereoselective pi stacking 
interactions and hydrogen bonds with the T-07 carbanion 5.i, resulting in the formation of a 
major T-06 methyl ester enantiomer 6.1 and a minor T-06 methyl ester enantiomer 6.2.  
  The T-06 methyl ester 6 was isolated from reaction side products using silica gel flash 
chromatography. The 1H-NMR spectrum of the purified T-06 methyl ester 6 is shown in Figure 
34. The absence of a doublet at δ5.6 ppm and a doublet at δ5.9 ppm, both of which are 
characteristic of the proton on the chiral carbon of T-07 5, in the 1H-NMR spectrum shown in 
Figure 34 suggests that the tertiary chiral center of T-07 5 was converted to the quaternary chiral 
center of the T-06 methyl ester 6.  
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The 1H-NMR spectrum shown in Figure 34 also features peaks at δ2.3 ppm and δ2.6 ppm that 
integrate for four protons. These chemical shifts are typical of protons on carbon atoms that are 
adjacent to esters and amides, suggesting that T-07 5 added at the β-carbon of methyl acrylate to 
produce the T-06 methyl ester 6.31  
  The T-06 methyl ester enantiomers 6.1 and 6.2 could not be separated because of the 













Figure 34. 1H-NMR spectrum of purified T-06 methyl ester 6 in CDCl3: δ2.3 ppm (m,1H on 
alkyl chain), δ2.6 ppm (s, 3H on alkyl chain), δ3.7 ppm (s, 3H of methoxy on methyl ester 
moeity), δ3.8 ppm (s, 3H of methoxy on m-anisidine ring), δ6.2 ppm (s, 1H, H in between the 
methoxy substituent and pyrrolidine ring of m-anisidine ring), δ6.6 ppm (d, 1H, H on m-
anisidine ring), δ7.2-8.0 ppm (m, 9H, 1H on m-anisidine ring, 4H within fluorobenzene, 4H 
within benzene ring of isoquinoline moiety), δ8.6 ppm (s, 1H, H of amide within isoquinoline 
side chain), δ9.1 ppm (s, 1H, H within nitrogen-containing ring of isoquinoline moiety), δ9.3 
ppm (s, 1H, H within nitrogen-containing ring of isoquinoline moiety). 
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HPLC, the stereoselectivity of the reaction could not be determined. In the future, this reaction 
should be repeated in order to determine its stereoselectivity. 	  
2.3 Future Directions  
  Neither the mandelate acrylate Michael addition nor the naphthalene acrylate Michael 
addition were not stereoselective. In these reactions, the ratio of T-07 to mandelate acrylate and 
naphthalene acrylate was 1:3 and 1:6, respectively. As a result of the excess amount of the pi 
stacking chiral auxiliary in solution, the auxiliaries may have preferentially formed pi stacking 
arrangements with each other rather than with the T-07 carbanion 5.i. Examples of the undesired 
self pi stacking of the mandelate acrylate and the naphthalene acrylate are shown in Figure 35. 
To avoid these unwanted pi stacking interactions, the T-07 to acrylate ratio should be adjusted to 
1:1 in future work. The increased amount of T-07 with respect to the acrylate would increase the 
likelihood that the 
mandelate acrylate and 
the naphthalene acrylate 
would form pi stacking 
interactions with T-07 
and decrease the 
likelihood that the 
acrylates would form pi stacking interactions with each other.    
  In addition to changing the ratio of T-07 to acrylate in order to discourage the undesired 
pi stacking interactions between acrylate molecules shown in Figure 35, future work should alter 
the solvent in which the acrylate is dissolved. Martinez and Iverson found that pi stacking 















Figure 35. Hypothesized self pi stacking interactions occurring 
between two molecules of A. mandelate acrylate and B. naphthalene 
acrylate. 
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solvents.28 Solvent polarity was characterized by ET(30) value, which is the molar electronic 
transition energy in kilocalorie/mole of the dissolved solvatochromic dye pyridinium N-
phenolate betaine at 25°C and 1 atm.28, 35 More pi stacking interactions occurred in solvents with 
higher ET(30) values. The mandelate acrylate B was dissolved in acetone, which has an ET(30) 
value of 42.2 kcal/mole, and the naphthalene acrylate was dissolved in 1,4 dioxane, which has an 
ET(30) value of 36.4 kcal/mole.35 To discourage the undesired self stacking interactions that may 
be occurring between acrylate molecules, the acrylate should be dissolved in a more non-polar 
solvent such as hexane, which has a ET(30) value of 31.0 kcal/mol.35  
  It is surprising that the naphthalene acrylate C Michael addition did not generate 
stereoselectivity given that the naphthalene acrylate C was dissolved in dioxane, which is only 
slightly more polar than hexane, as demonstrated by ET(30) values of 36.4 and 31.0 kcal/mole, 
respectively. The lack of stereoselectivity presumably results from the lack of desired pi stacking 
interactions between the T-07 carbanion 5.i and the naphthalene acrylate C. Although pi stacking 
interactions between acrylate molecules were minimized by dissolving the naphthalene acrylate 
in dioxane, all pi stacking interactions, including the desired pi stacking interaction between the 
T-07 carbanion 5.i and the naphthalene acrylate C, were discouraged because the entire reaction 
was performed in dioxane. To simultaneously encourage the desired pi stacking interactions and 
discourage the undesired self pi stacking interactions, T-07 should be dissolved in a relatively 
polar solvent such as ethanol, which has an ET(30) value of 51.9 kcal/mol, and the naphthalene 
acrylate should be dissolved in a relatively non-polar solvent such as dioxane or hexane.  
  Unlike the naphthalene acrylate Michael addition, the mandelate acrylate Michael 
addition was performed in a 1:4 mixture of DMSO:acetone, corresponding to an ET(30) value of 
42.9 kcal/mol.35 It is surprising that this Michael addition did not generate stereoselectivity given 
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that the entire reaction was performed in a relatively polar solvent that was expected to 
encourage the desired pi stacking interactions between the T-07 carbanion 5.i and the mandelate 
acrylate B. It is important to note that the mandelate acrylate B was dissolved in acetone before it 
was added to the T-07 carbanion 5.i solution. Because acetone is a relatively polar solvent, the 
mandelate acrylate B may have formed undesired self stacking interactions before it was added 
to the reaction mixture. To simultaneously encourage the desired pi stacking interactions and 
discourage the undesired pi stacking interactions, the mandelate acrylate should be dissolved in a 
relatively non-polar solvent such as dioxane or hexane and T-07 should remain dissolved in 
acetone or another polar solvent like ethanol. Solubility needs to be taken into account if solvent 
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3. EXPERIMENTAL 
 
3.1 General  
All solvents and reagents that could be purchased were purchased from Sigma-Aldrich. All NMR 
spectra were generated using a 300 MHz Bruker WIN-NMR Spectrometer. Gas chromatography-
mass spectrometry (GC-MS) data was collected using an Agilent 6890N Network GC System 
coupled to an electron impact Agilent 5937 Network Mass Selective Detector. All GC-MS were 
collected using the program “RAYANNE” with the following parameters: Tinitial = 120°C, Tfinal = 
325°C, rate = 20°C/sec.; split mode inlet; mobile phase = He(g); constant flow mode, flow rate = 
1.0 mL/min; injection volume = 1.0 µL; pressure = 11.6 psi. Liquid chromatography-mass 
spectrometry data was collected using an Agilent Eclipse C18 column with a 0-100% acetonitrile 
in water gradient over 20 minutes. Eluents detected using UV-absorbance at 254 nm and 
identified using electrospray ionization mass spectrometry. Purification of compounds via silica 
gel flash chromatography was accomplished using the Biotage Flash Chromatography system 
with pre-packed silica gel (size: 40-63 µm) of varying dimensions and lengths. Catalytic 
hydrogenation was performed with Parr Instrument Company Pressure Reaction Apparatus. High 
Performance Liquid Chromatography (HPLC) was performed using a Waters 1525 Binary HPLC 
Pump coupled to a Waters 2487 Dual λ Absorbance Detector. All HPLC data was obtained using 
a CHIRALPAK IA column (4.6 mm by 250 mm) with amylose tris (3,5-
dimethylphenylcarbamate) immobilized on 5 µm silica support as the stationary phase and 
1:10:345:645 solution of glacial acetic acid:ethanol:dichloromethane:hexanes as the mobile 
phase. The HPLC was run using the following parameters: pressure = 450 psi; flow rate = 1 
mL/min; injection volume = 50 µL.  
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3.2 Synthesis and purification of T-07  
T-07 was synthesized in five steps, as shown in Figure 36. The experimental procedure 
for the synthesis and purification of each intermediate is detailed in the following pages.  
 
Figure 36. Synthesis of T-07. The numbers correspond to the following compounds: 
diphenylamine 1, isatin 2, oxime 3, amine hydrochloride 4, and T-07 5.  
Synthesis and purification of diphenylamine 1 
In a 1.0 L oven-dried round bottom flask equipped with a stir bar, 4.00 g 
methoxybenzene boronic acid (0.026 mol), 0.32 g copper (II) acetate (0.0018 mol), and 0.80 g 
myristic acid (0.0035 mol) were added. A septum cap was placed on the reaction flask before the 
sequential syringe addition of 35 mL anhydrous toluene, 2.03 mL 2,6 lutidine (0.018 mol), and 
1.69 mL fluoroaniline (0.018 mol). The reaction was vigorously stirred for 24 hours at room 
temperature, over the course of which the color of the reaction mixture changed from light blue 
to muddy green. Next, 120 mL of ethyl acetate was added, and the reaction mixture was then 
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reduced pressure and the presence of diphenylamine in the crude reaction mixture was confirmed 
with GC-MS.  
The crude diphenylamine was purified via silica gel gravity chromatography. An epoxy 
coated glass column of 35 mm diameter, 400 mm length, and 400 mL column volume was 
packed with silica gel and primed with roughly 1000 mL of 1% ethyl acetate in hexanes. After 
loading the crude diphenylamine dissolved in 1% ethyl acetate in hexanes onto the primed 
column, the compound was purified using 750 mL of 1% ethyl acetate in hexanes followed by 
1500 mL of 3% ethyl acetate. The presence of diphenylamine 1 in the eluents was monitored 
with UV-visible absorption at 254 nm and confirmed with GC-MS and 1H-NMR spectroscopy. 
GC-MS (Appendix 1): mass ion 217 m/z, base peak 217 m/z. 1H-NMR spectrum in CDCl3 
(Appendix 2): δ3.9 ppm (s, 3H, methoxy), δ6.1 ppm (s, 1H ortho to the methoxy and ortho to the 
nitrogen), δ6.7-7.6 ppm (m, 7H, 1H ortho to the methoxy and para to the nitrogen, 1 H meta to 
both the methoxy and the nitrogen, 1H para to the methoxy and ortho to the nitro, 1H ortho to the 
nitrogen and meta to the fluorine, 1H meta to the nitrogen and para to the fluorine, 1H para to the 
nitrogen and meta to the fluorine, 1H meta to the nitrogen and ortho to the fluorine).  
Synthesis and purification of isatin 2  
In a 250 mL oven-dried round bottom flask equipped with a stir bar, 2.93 mL oxalyl 
chloride (0.0341 mol) was dissolved in 13.86 mL amylene stabilized chloroform under nitrogen. 
The reaction was cooled to 0°C with an ice bath and stirred for 15 minutes before the dropwise 
addition of 3.44 g pure diphenylamine 1 (0.0156 mol) dissolved in 13.86 mL amylene stabilized 
chloroform. The mixture was kept on ice until gas evolution ceased, which was approximately 
five minutes. The reaction mixture was then stirred for two hours at room temperature, after 
which the solvent was evaporated under reduced pressure. Next, 2 mL amylene stabilized 
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chloroform was added and evaporated twice so that a total of 4 mL amylene stabilized 
chloroform was added. The resulting olive green oily intermediate was promptly dissolved in 32 
mL dichloromethane and cooled on ice. Upon flushing the reaction flask with nitrogen, 2.11 g 
aluminum (III) chloride (0.016 mol) was added. The reaction mixture was stirred under nitrogen 
at room temperature for 48 hours, after which the mixture was poured over 45 g of ice dissolved 
in 11.5 mL of 2 M HCl. Isatin was extracted with dichloromethane and the resulting organic 
layer was washed once with 10% sodium bicarbonate and once with water. The organic layer 
was then dried with anhydrous magnesium sulfate and filtered through phase paper. The solvent 
was evaporated under reduced pressure and the presence of isatin in the crude reaction mixture 
was confirmed through GC-MS.  
The crude isatin was purified via silica gel gravity chromatography. An epoxy coated 
glass column of 35 mm diameter, 400 mm length, and 400 mL column volume was packed with 
silica gel and primed with approximately 1000 mL of 66% dichloromethane in hexanes. After 
loading the crude isatin dissolved in 66% dichloromethane in hexanes onto the primed column, 
the compound was purified using 1500 mL of 66% dichloromethane in hexanes followed by 500 
mL of 80% dichloromethane in hexanes followed by 500 mL of 90% dichloromethane in 
hexanes followed by 1500 mL of 100% dichloromethane. The presence of isatin 2 in the eluents 
was monitored with UV-visible absorption at 254 nm and confirmed with GC-MS and 1H-NMR 
spectroscopy. GC-MS (Appendix 3): molecular ion peak at 271 m/z, base peak at 243 m/z.  1H-
NMRspectrum in CDCl3 (Appendix 4): δ3.86 ppm (s, 3H, methoxy), δ6.2 ppm (d, 1H, H 
between methoxy and N), δ6.6 ppm (d, 1H, H ortho to methoxy and para to N), δ7.3-7.5 ppm (m, 
4H, H on fluorobenzene), δ7.7 ppm (d, 1H, H ortho to carbonyl).  
 
	   62 
Synthesis of oxime 3 
In a 250 mL oven-dried round bottom flask equipped with a stir bar, 2.99 g pure isatin 2 
(0.011 mol), 0.85 g hydroxylamine hydrochloride (0.012 mol), and 1.23 g sodium carbonate 
(0.012 mol) were dissolved in 43 mL of 95% ethanol. The reaction was stirred at room 
temperature for 24 hours. The reaction was quenched with roughly 60 mL of water, and the 
crude oxime was collected in a pre-weighed Buchner funnel via vacuum filtration. The oxime 
was dried for 48 hours before massing. The presence of the oxime 3 was confirmed with 1H-
NMR spectroscopy. No purification was necessary. 1H-NMR spectrum in CDCl3 (Appendix 5): 
δ3.7 ppm (singlet, 3H, methoxy on the non-fluorinated aromatic ring), δ3.5-3.8 ppm (broad s, 
1H, hydroxyl), δ3.9 ppm (s, 3H, methoxy), δ6.1 ppm (s, 1H, ortho to the methoxy and ortho to 
the nitrogen), δ6.6 ppm (d, 1H, H ortho to the methoxy on the benzene ring), δ7.2-7.4 ppm (m, 
4H on fluorobenzene), δ8.1 ppm (d, 1 H ortho to oxime).  
Synthesis of amine hydrochloride 4 
In a 500 mL catalytic hydrogenation bottle, 3.02 g oxime 3 (0.011 mol) was dissolved in 
120 mL of 100% ethanol. After adding 0.61 g of 5% Pd on carbon and roughly 1.9 mL of 12 M 
HCl, the oxime was subjected to 50 psi of H2 for approximately 24 hours, after which time the 
Pd on carbon was removed via vacuum filtration. The solvent in the resulting solution was 
evaporated under reduced pressure. The crude amine hydrochloride was triturated twice with 20 
mL anhydrous diethyl ether. The resulting product was dissolved in 20 mL toluene, and the 
solvent was evaporated under reduced pressure at 35°C. The presence of amine hydrochloride 4 
was confirmed with 1H-NMR spectroscopy. No purification was necessary. 1H-NMR spectrum 
in d6-DMSO (Appendix 6): δ3.7 ppm (s, 3H on methoxy), δ5.2 ppm and δ5.3 ppm (two s, 1H α 
to protonated amine), δ6.2 ppm (s, 1H ortho to the methoxy and ortho to the nitrogen within the 
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adjacent five-membered ring), δ6.8 ppm (d, 1H ortho to the methoxy and para to the nitrogen 
within the adjacent five membered ring), δ7.4-7.8 ppm (m, 5H, 1H meta to the methoxy and 
meta to the nitrogen within the adjacent five-membered ring, 4H on the fluorobenzene), δ9.4 
ppm (s, 3H from protonated amine). 
Synthesis and purification of T-07 5 
In a 100 mL oven-dried round bottom flask, 2.90 g amine hydrochloride 4 (0.0093 mol) 
and 1.98 g isoquinoline-3-carboxylic acid (0.010 mol) were dissolved in 29 mL dichloromethane 
under nitrogen. After cooling the reaction mixture to 0°C for 15 minutes on an ice bath, 1.47 mL 
diisopropylethylamine (0.0085 mol) was added, causing the reaction mixture to change color 
from pale yellow to pale red. Next, 1.40 g hydroxybenzotriazole (0.010 mol) and 1.98 g 1-ethyl-
3-(3-dimethylaminoporpyl)carbodiimide (0.010 mol) were added to the reaction mixture, causing 
the color of the reaction mixture to become magenta. The reaction mixture was warmed to room 
temperature and stirred for 15 hours. The reaction was quenched with 50 mL of water, and T-07 
was extracted with dichloromethane. The organic layer was washed twice with water, dried with 
anhydrous magnesium sulfate, and filtered through phase paper. The solvent was evaporated 
under reduced pressure and the presence of T-07 in the crude reaction mixture was confirmed 
with 1H-NMR spectroscopy.  
The crude T-07 was purified via silica gel flash chromatography. A pre-packed Biotage 
25+M silica column was primed with 400 mL of 25% ethyl acetate in hexanes. The crude 
product was dissolved in dichloromethane and loaded onto the corresponding pre-packed silica 
samplet. Before running the column, the samplet was dried on top of the oven for 30 minutes to 
ensure evaporation of dichloromethane. The following gradient was used to separate T-07 from 
reaction side products: 225 mL of 25% ethyl acetate in hexanes, 750 mL of 25-40% ethyl acetate 
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in hexanes, and 225 mL of 40% ethyl acetate in hexanes. The presence of T-07 5 in the eluents 
was confirmed with 1H-NMR spectroscopy. 1H-NMR spectrum in CDCl3 (Appendix 7): δ3.7 
ppm (s, 3H on methoxy), δ5.7-5.9 ppm (two d, 1 H α to amide), δ6.2 ppm (s, 1H ortho to the 
methoxy and ortho to the nitrogen within the adjacent five-membered ring), δ6.6 ppm (d, 1H 
ortho to the methoxy and para to the nitrogen within the adjacent five membered ring), δ7.3-7.8 
ppm (m, 9H, 1H meta to the methoxy and meta to the nitrogen within the adjacent five-
membered ring, 4H on the fluorobenzene, 4H on the non-nitrogen containing ring of the 
isoquinoline), δ8.6 ppm (d, 1H on the amide), δ9.0-9.2 ppm (two d, 2H on the nitrogen 
containing ring of the isoquinoline). 
3.3 Synthesis and purification of mandelate acrylate B 
 
In a 500 mL oven-dried round bottom flask equipped with a stir bar, 3.84 g ethyl-(S)-(+)-
mandelate (0.021 mol) was dissolved in 50 mL THF under nitrogen. The mixture was chilled on 
ice before 0.84 g of 60% sodium hydride (0.021 mol) was added. After the mixture was stirred 
on ice for 30 minutes, 3.54 mL acryloyl chloride (0.042 mol) was added. The reaction mixture 
was warmed to room temperature and stirred for 2 hours under nitrogen. The reaction was 
quenched with water, and the product was extracted with dichloromethane. The aqueous layer 
was washed twice with dichloromethane. The combined organic layers were then dried with 
anhydrous magnesium sulfate and filtered through phase paper. The solvent was evaporated and 
the presence of the mandelate acrylate in the crude reaction mixture was confirmed with GC-MS.  
The crude mandelate acrylate was purified via silica gel flash chromatography. A pre-
packed silica column of 40 mm diameter, 150 mm length, and 132 mL column volume was 
primed with 530 mL of 20% ethyl acetate in hexanes. The crude mandelate acrylate was 
dissolved in dichloromethane and loaded onto the corresponding pre-packed silica samplet. 
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Before running the column, the samplet was dried on top of the oven for 30 minutes. The 
mandelate acrylate was isolated by running the following gradient: 396 mL of 20% ethyl acetate 
in hexanes, 1320 mL of 20-30% ethyl acetate in hexanes, and 396 mL of 30% ethyl acetate in 
hexanes. The presence of mandelate acrylate B was confirmed with GC-MS and 1H-NMR 
spectroscopy (Appendix 10, refer to Results and Discussion for analysis). The pure mandelate 
acrylate was stored in the refrigerator until further use to prevent polymerization.  
3.4 Synthesis and purification of naphthalene acrylate C 
 
In a 25 mL oven-dried round bottom flask, 1.00 g (R)-(+)-alpha-methyl-2-naphthalene-
methanol (0.0058 mol) was dissolved in 10 mL THF under nitrogen. The mixture was chilled on 
ice before 0.23 g of 60% sodium hydride (0.0058 mol) was added. After the mixture was stirred 
on ice for 30 minutes, 0.95 mL acryloyl chloride (0.012 mol) was added. The reaction mixture 
was warmed to room temperature and stirred for 2 hours under nitrogen. The reaction was 
quenched with water, and the product was extracted with dichloromethane. The aqueous layer 
was washed twice with dichloromethane. The organic layer was then dried with anhydrous 
magnesium sulfate and filtered through phase paper. The solvent was evaporated and the 
presence of the naphthalene acrylate in the crude reaction mixture was confirmed with GC-MS.  
The crude naphthalene acrylate was purified via silica gel flash chromatography. A pre-
packed silica column of 40 mm diameter, 150 mm length, and 132 mL column volume was 
primed with 530 mL of 100% hexanes. The crude naphthalene acrylate dissolved in 100% 
hexanes was loaded onto the corresponding pre-packed silica samplet.  The naphthalene acrylate 
was isolated by running the following gradient: 396 mL of 100% hexanes, 1320 mL of 0-10% 
ethyl acetate in hexanes, and 396 mL of 10% ethyl acetate in hexanes. The presence of 
naphthalene acrylate C in the eluents was confirmed with GC-MS and 1H-NMR spectroscopy 
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(Appendix 12, refer to Results and Discussion for analysis). The pure naphthalene acrylate was 
stored in the refrigerator until further use to prevent polymerization. 
3.5 Michael addition with isobornyl acrylate A 
In a 5 mL round bottom flask, 0.060 g pure T-07 5 (0.00014 mole) and 0.058 g potassium 
carbonate (0.00042 mole) were dissolved in 1.2 mL 1,4 dioxane. The reaction was stirred for 10 
minutes at room temperature before 0.18 mL isobornyl acrylate A (0.00084 mole) was added 
dropwise with a syringe. The reaction was covered with a septum cap and stirred at room 
temperature for 24 hours. The reaction was quenched with water, and the product was extracted 
with dichloromethane. The aqueous layer was washed twice with dichloromethane, and the 
resulting organic layers were combined. The organic layer was then dried with anhydrous 
magnesium sulfate and filtered through phase paper. The solvent was evaporated under reduced 
pressure. 
The crude product was purified via silica gel flash chromatography. A pre-packed 
Biotage SNAP 10 g silica column was primed with 100 mL of 30% ethyl acetate in hexanes. The 
crude product was dissolved in dichloromethane and loaded onto the corresponding pre-packed 
silica samplet. Before running the column, the samplet was dried on top of the oven for 30 
minutes. The T-06 isobornyl ester was isolated by running the following gradient: 45 mL of 30% 
ethyl acetate in hexanes, 150 mL of 30-50% ethyl acetate in hexanes, and 45 mL of 50% ethyl 
acetate in hexanes. The presence of the T-06 isobornyl ester 6.A was confirmed with 1H-NMR 
spectroscopy (refer to Results and Discussion for analysis).  
Chiral HPLC was used to separate the T-06 isobornyl ester diastereomers 6.A.1 and 
6.A.2. The Waters Breeze HPLC was equilibrated for 48 hours with a mobile phase containing 
1:10:345:645 parts glacial acetic acid:ethanol:dichloromethane:hexanes. Pure T-06 isobornyl 
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ester 6.A was dissolved in the mobile phase, and 50 µL of solution was injected onto the column. 
The column was run for 15 minutes at 450 psi with the detection wavelength set at 254 nm. The 
eluents were manually collected.  
3.6 Michael addition with mandelate acrylate B 
In a 100 mL round bottom flask, 0.24 g pure T-07 5 (0.00057 mole) and 0.24 g potassium 
carbonate (0.0017 mole) were dissolved in 1 mL DMSO. The reaction was stirred at room 
temperature for 10 minutes before 0.40 g pure mandelate acrylate B (0.0017 mole) dissolved in 
3.0 mL acetone was added dropwise to the reaction mixture. The reaction was stirred at room 
temperature for 24 hours. The reaction was quenched with water, and the product was extracted 
with dichloromethane. The aqueous layer was washed twice with water and, and the resulting 
organic layers were combined. The organic layer was then dried with anhydrous magnesium 
sulfate and filtered through phase paper. The solvent was evaporated under reduced pressure.   
The crude product was purified via silica gel flash chromatography. A pre-packed 
Biotage 25+M silica column was primed with 400 mL of 1% ethyl acetate in dichloromethane. 
The crude product was dissolved in dichloromethane and loaded onto the corresponding pre-
packed silica samplet. The following gradient was used to separate the T-06 mandelate ester 
diastereomers: 225 mL of 1% ethyl acetate in dichloromethane, 750 mL of 1-3% ethyl acetate in 
dichloromethane, 225 mL of 3% ethyl acetate in dichloromethane, and 750 mL of 3-10% ethyl 
acetate in dichloromethane. The presence of the T-06 mandelate ester diastereomers 6.B.1 and 
6.B.2 were confirmed with 1H-NMR spectroscopy (refer to Results and Discussion for analysis).  
3.7 Michael addition with naphthalene acrylate C 
In a 10 mL round bottom flask, 0.13 g pure T-07 5 (0.00031 mol) and 0.13 g potassium 
carbonate (0.00093 mol) were dissolved in 2.56 mL 1,4 dioxane. The reaction was stirred at 
	   68 
room temperature for 10 minutes before 0.42 g pure naphthalene acrylate C (0.0019 mol) 
dissolved in 1.5 mL 1,4 dioxane was added dropwise with a pipet. The reaction was covered with 
a septum cap and stirred at room temperature for 24 hours. The reaction was quenched with 
water, and the product was extracted with dichloromethane. The aqueous layer was washed twice 
with dichloromethane, and the resulting organic layers were combined. The organic layer was 
then dried with anhydrous magnesium sulfate and filtered through phase paper. The solvent was 
evaporated under reduced pressure.  
The crude product was purified via silica gel flash chromatography. A pre-packed 
Biotage 12+M silica column was primed with 100 mL of 5% ethyl acetate in hexanes. The crude 
product was dissolved in dichloromethane and loaded onto the corresponding pre-packed silica 
samplet. Before running the column, the samplet was dried on top of the oven for 30 minutes. 
Impure T-06 naphthalene ester was isolated by running the following gradient: 45 mL of 5% 
ethyl acetate in hexanes, 150 mL of 5-20% ethyl acetate in hexanes, 150 mL of 20-60% ethyl 
acetate in hexanes, and 45 mL of 60% ethyl acetate in hexanes. A new pre-packed Biotage 12+M 
silica column was then primed with 100 mL of 40% ethyl acetate in hexanes. The impure T-06 
naphthalene ester isolated from the first silica gel flash chromatography column was dissolved in 
dichloromethane and loaded onto the corresponding pre-packed silica samplet. Before running 
the column, the samplet was dried on top of the oven for 30 minutes. Pure T-06 naphthalene 
ester was isolated by running the following gradient: 45 mL of 40% ethyl acetate in hexanes, 150 
mL of 40-60% ethyl acetate in hexanes, and 45 mL of 60% ethyl acetate in hexanes. The 
presence of the T-06 naphthalene ester 6.C was confirmed with 1H-NMR spectroscopy (refer to 
Results and Discussion for analysis).  
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Chiral HPLC was used to separate the T-06 naphthalene ester diastereomers 6.C.1 and 
6.C.2. The Waters Breeze HPLC was equilibrated for 48 hours with a mobile phase containing 
1:10:345:645 parts glacial acetic acid:ethanol:dichloromethane:hexanes. Pure T-06 naphthalene 
ester 6.C was dissolved in the mobile phase, and 50 µL of solution was injected onto the column. 
The column was run for 22 minutes at 450 psi with the detection wavelength set at 254 nm. The 
eluents were manually collected and the presence of T-06 naphthalene ester diastereomers was 
confirmed with LC-MS (refer to Results and Discussion for analysis).  
3.8 Michael addition with dinaphthyl pyrrolidine methanol and methyl acrylate  
In a 5 mL round bottom flask, 0.050 g pure T-07 5 (0.00012 mol) and 0.041 g (S)-(-)-α,α-
di-(2-naphthyl)-2-pyrrolidine methanol (0.00012 mol) were dissolved in 0.5 mL 1,4 dioxane. 
The mixture was stirred at room temperature for 17 minutes, at which point 0.049 g potassium 
carbonate (0.00035 mol) was added. After stirring the reaction for 10 minutes, 0.06 mL methyl 
acrylate (0.00070 mol) was added dropwise with a pipet. The reaction flask was sealed with a 
septum cap and stirred at room temperature for 24 hours. The reaction was quenched with water, 
and the product was extracted with dichloromethane. The aqueous layer was washed twice with 
dichloromethane, and the resulting organic layers were combined. The organic layer was then 
dried with anhydrous magnesium sulfate and filtered through phase paper. The solvent was 
evaporated under reduced pressure and the presence of T-06 methyl ester in the crude reaction 
mixture was confirmed with 1H-NMR spectroscopy.  
The crude product was purified via silica gel flash chromatography. A pre-packed 
Biotage SNAP 10 g silica column was primed with 100 mL of 40% ethyl acetate in hexanes. The 
crude product was dissolved in dichloromethane and loaded onto the corresponding pre-packed 
silica samplet. Before running the column, the samplet was dried on top of the oven for 30 
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minutes. Impure T-06 methyl ester was isolated by running the following gradient: 45 mL of 
40% ethyl acetate in hexanes, 150 mL of 40-60% ethyl acetate in hexanes, and 45 mL of 60% 
ethyl acetate in hexanes. A new pre-packed Biotage SNAP 10 g silica column was then primed 
with 100 mL of 0.5% methanol in dichloromethane. The impure T-06 methyl ester isolated from 
the first silica gel flash chromatography column was dissolved in dichloromethane and loaded 
onto the corresponding pre-packed silica samplet. Before running the column, the samplet was 
dried on top of the oven for 30 minutes. Pure T-06 methyl ester was isolated by running the 
column with 90 mL of 0.5% methanol in dichloromethane. The presence of the T-06 methyl 
ester 6 was confirmed with 1H-NMR spectroscopy (refer to Results and Discussion for analysis).  
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Appendix 1: Mass spectrum of diphenylamine 1 
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Appendix 3: Mass spectrum of isatin 2   
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Appendix 5: 1H-NMR spectrum of oxime 3 in CDCl3 
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Appendix 7: 1H-NMR spectrum of T-07 5 in CDCl3 
 
 














	   76 
Appendix 9: 1H-NMR spectrum of mandelate alcohol in CDCl3 
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Appendix 11: 1H-NMR spectrum of naphthalene alcohol in CDCl3 
 
 
Appendix 12: 1H-NMR spectrum of naphthalene acrylate in CDCl3 
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